CONTRIBUTION OF SOMATOSTATIN DEFICITS AND EIF2 SIGNALING TO ANXIETY/DEPRESSIVE-LIKE BEHAVIORS by Lin, Li-Chun
 CONTRIBUTION OF SOMATOSTATIN DEFICITS AND EIF2 
SIGNALING TO ANXIETY/DEPRESSIVE-LIKE BEHAVIORS   
  
 
 
 
 
 
 
 
by 
Li-Chun Lin 
B.S. in Psychology, National Chung Cheng University, 2004 
M.S. in Physiology, National Cheng Kung Univeristy, 2006 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
School of Medicine in partial fulfillment  
of the requirements for the degree of 
Doctor of Philosophy 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2014 
 
 ii 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF MEDICINE 
 
 
 
 
 
 
 
 
This dissertation was presented 
 
by 
 
 
Li-Chun Lin 
 
 
 
It was defended on 
May 1st, 2014 
and approved by 
Dr. Gregg E. Homanics, Professor, Anesthesiology, Pharmacology and Chemical Biology 
Dr. Linda Rinaman, Director and Professor, Neuroscience 
Dr. Colleen McClung, Associate Professor, Psychiatry 
Dr. Peter Gianaros, Associate Professor, Psychology  
Dr. Ronald Duman, Director and Professor, Neurobiology, Pharmacology and 
Psychiatry, Yale University 
 Dissertation Advisor: Dr. Etienne Sibille, Associate Professor, Psychiatry 
 
 
 iii 
Copyright © by Li-Chun Lin 
2014 
 iv 
 
Somatostatin is a secretory neuropeptide and marker of gamma-aminobutyric acid 
(GABA) interneurons that contribute to information processing of local cortical circuits. SST 
deficits are frequently observed in depression and other neurological disorders with mood 
disturbances, but the origin of SST-related pathological changes and their role in disease 
processes remain elusive. We used mice lacking Sst (SstKO) to investigate the contribution of low 
SST to anxiety/depressive-like phenotypes (defined as emotionality) under baseline and stressed 
conditions. High emotionality was found in SstKO mice at baseline and after unpredictable 
chronic mild stress exposure. Compared to wild-type mice, unstressed SstKO mice showed high 
basal plasma corticosterone and reduced gene expression of Bdnf, Cortistatin, and Gad67 in the 
cingulate cortex. Compared to pyramidal neurons, cell-specific transcriptome analyses indicated 
that SST neurons in the cingulate cortex are more vulnerable to chronic stress. Protein translation 
through eukaryotic initiation factor 2 (EIF2) signaling, a pathway previously implicated in 
neurodegenerative diseases, was most affected and suppressed in stress-exposed SST neurons. 
Activating EIF2 signaling with an EIF2 kinase inhibitor mitigated mouse anxiety/depressive-like 
behaviors that were induced by stress. Together, our results suggest a causal relationship 
between SST deficits and mood-related phenotypes by first showing that SstKO mice exhibit 
behavioral, neuroendocrine and molecular phenotypes parallel those seen in human patients with 
major depression. Our results further suggest a novel antidepressant function for EIF2-related 
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Li-Chun Lin, M.S., Ph.D. 
University of Pittsburgh, 2014
 
 v 
protein translational control, and may prove important in elucidating mechanisms of how chronic 
stress triggers and sustains selective vulnerability of SST neurons associated with mood 
symptoms in stress-related neuropsychiatric disorders. 
 vi 
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1.0  INTRODUCTION 
Somatostatin (SST) is an inhibitory neuropeptide and a marker for GABAergic interneuronal 
subpopulations. SST-expressing interneurons preferentially target the dendrites of pyramidal 
neurons, contributing to information processing at the microcircuit level (Di Cristo et al., 2004; 
Markram et al., 2004; Tan et al., 2008; Murayama et al., 2009; Xu et al., 2013). SST deficits are 
frequently observed in depression and other neurological disorders with mood disturbances. 
However, mechanistically how SST deficits contribute to the disease processes remains mostly 
unknown. Therefore, knowledge of how SST neurons contribute to aberrant mood regulation is 
important in uncovering the pathophysiology of mood dysregulation. 
1.1 OVERVIEW OF MAJOR DEPRESSIVE DISORDER 
1.1.1 Epidemiology of major depressive disorder 
Major depressive disorder (MDD) is a common and severe psychiatric disorder with high 
worldwide morbidity and lifetime prevalence. In the United States, the 12-month prevalence of 
MDD was estimated to be 6.7% (Kessler et al., 2005b).  Among the surveyed patients, 30.4% of 
affected adults (approximately 2% of US adult population) were classified as “severe” (Kessler 
et al., 2005a). Women are 70% more likely than men to experience depression (Kessler et al., 
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2003). The burden on society accounts for 5 % of years lost due to disability (YLD) (Ferrari et 
al., 2013). Hence, improving the understanding, diagnosis, and treatment of MDD is a public 
health priority.  
1.1.2 Clinical Presentation and treatment of MDD 
MDD etiology remains poorly understood. Clinical presentation of MDD can include a variety of 
symptoms such as negative affective states (anhedonia and anxiety), abnormal hypothalamic-
pituitary-adrenal (HPA) axis, insomnia, and emergence of cognitive and physiological 
impairments. Moreover, MDD and anxiety disorders commonly co-occur. From both etiological 
and clinical perspectives, MDD is a heterogeneous disease. Therefore while many MDD 
biomarkers have been investigated, standalone markers seem unlikely to be applicable to a large-
scale group of patients.  
The first-line treatment of MDD is a combination of psychotherapy and pharmacotherapy 
of selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine or selective noradrenaline 
reuptake inhibitors (SNRIs) such as venlafaxine. Upon diagnosis of MDD, 4-8 weeks of initial 
treatment is needed to assess its effect. To reduce the risk of relapse, patients with MDD will 
need to continue with antidepressant medications during the acute phase, and for another 4-9 
months during the continuation phase. To reduce the risk of a recurrent depressive episode, 
patients with chronic MDD will also receive a maintenance phase of treatment after completing 
the continuation phase. A common mechanism of antidepressants is to increase the availability of 
monoamines in the synaptic cleft. However, side effects of antidepressants include body weight 
changes, insomnia, sexual dysfunction, nausea, constipation, and cardiovascular toxicity 
(Masand & Gupta, 2002; Cassano & Fava, 2004). Given the clinical and etiological 
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heterogeneity, only 50% of MDD patients achieve remission after first-line antidepressant 
treatments (Fava & Davidson, 1996; Trivedi et al., 2006).  
Although treatments that target neuropeptide receptors were well supported by basic 
neuroscience research, compounds that target neuropeptide receptors failed to demonstrate 
efficacy during clinical trials (Griebel & Holsboer, 2012). Nearly all pharmaceutical companies 
now continue to pursue classical monoamine-based drugs. As alternatives to pharmacological 
treatments, non-invasive neuromodulation procedures, for example electroconvulsive and 
repetitive transcranial magnetic stimulation have been shown to be effective in treating MDD 
(Hoffman & Cavus, 2002; Tamminga et al., 2002).  Nevertheless, potentially serious side effects 
include memory impairment and headache. Deep brain stimulation has recently been studied as 
an option for treatment-resistant depression (Mayberg et al., 2005; Lozano et al., 2008), but it is 
an invasive surgery procedure and still at an early experimental stage.  
1.1.3 Risk factors for MDD 
The HPA axis has been implicated in MDD. Although not all adults with elevated cortisol levels 
are MDD patients, MDD patients disproportionately show chronic HPA axis hyperactivity and 
an inability for this system to return to normal functioning after being exposed to a stressor (Gold 
& Chrousos, 2002).  In addition, adults with the most severe depression also tend to have highest 
cortisol levels (Pruessner et al., 2003). The principle regulator of the HPA axis is corticotropin-
releasing hormone (CRH), which leads to the release of glucocorticoids (GC; cortisol in humans, 
corticosterone in rodents) from the adrenal cortex. GC maintains the basal activity of the HPA 
axis and influences stress-related responsiveness. In addition to altered expression of CRH and 
GC receptors (Webster et al., 2002; Wang et al., 2008; Hauger et al., 2009), altered circadian 
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patterns of cortisol are also frequently observed in MDD patients (Bhagwagar et al., 2003; Luby 
et al., 2003; Brouwer et al., 2005). Successful antidepressant treatment normalizes HPA axis 
hyperactivity (Heuser et al., 1996; Ising et al., 2007), supporting the hypothesis that 
a dysfunctional HPA/CRH system is involved in MDD etiology.  However, whether HPA axis 
hyperactivity precedes a depressive episode or is a consequence of it remains unclear.  
1.1.4 Animal model of depression 
The association between stress and MDD onset/episodes is well-established (Kendler et al., 
1999; Hammen, 2005). The unpredictable chronic mild stress (UCMS) model uses 
environmental and social stressors (e.g., wet bedding, single housing) to increase 
anxiety/depressive-like behaviors, decreased consumption of palatable food, and induce 
physiological changes (e.g., coat state) in rodents (Santarelli et al. 2003; Pothion et al. 2004; 
Mineur et al. 2006). Most of the UCMS-induced behaviors can be blocked and reversed by 
chronic antidepressant treatment (Surget et al. 2009). Importantly, the UCMS paradigm also 
mimics sex differences in human MDD patients (Joeyen-Waldorf et al., 2009; Guilloux et al., 
2011), illustrating a strong face validity for the human syndrome. Chronic corticosterone 
exposure is a neuroendocrine stress. Although both models lead to neuroendocrine, physical and 
behavioral depression-like alterations, UCMS has better construct, face and overall mechanistic 
validity compared to corticosterone exposure since social-environmental stress  induces multi-
systems disruptions that are not limited to neuroendocrine changes (Willner et al., 1987; Pothion 
et al., 2004). 
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1.1.5 Molecular biology of MDD 
Genetic predisposition is a critical component of MDD pathogenesis. Several genetic factors 
have been suggested to be involved in the pathophysiology of depression and the mechanism of 
antidepressant actions, including serotonergic (Caspi et al., 2003), GABAergic (Sanacora et al., 
2004; Luscher et al., 2011) and BDNF signaling pathways (Duman et al., 1997; Duman et al., 
2000; Hashimoto et al., 2004). Given the complexity of MDD, single-gene effects may not fully 
explain the heterogeneous clinical phenotypes of MDD (Fava & Kendler, 2000; Lopez-Leon et 
al., 2008). In addition, genetic risk factors for MDD may increase the impact after being exposed 
to stressors (Kendler & Karkowski-Shuman, 1997; Caspi et al., 2003). Thus, this heterogeneity 
of accumulated gene-environment interactions reflects the unique complexities of MDD and 
points to the inherent difficulties in treating MDD as a homogenous entity. A challenge remains 
in understanding how distal effects of multiple genes converge to affect mood dysregulation.   
1.1.6 Altered cingulate cortex in MDD 
The medial prefrontal cortex (mPFC) is involved in top-down regulation for flexible behavior 
(Akana et al., 2001; Diorio et al., 1993; McKlveen et al., 2013). The mPFC is comprised of three 
subdivisions based on its connectivity, cytoarchitecture, and function: the anterior cingulate 
[human Brodmann area (BA) 24], prelimbic (human BA32), and infralimbic (human BA25) 
cortices (Uylings et al., 2003; Vertes, 2004; Gabbott et al., 2005). The anterior cingulate cortex 
(ACC) contains glucocorticoid receptors (GR) and plays a critical role in the inhibitory 
regulation of HPA axis via GR-mediated negative feedback effects of GC actions during stress 
(Diorio et al., 1993; Devinsky et al., 1995). In addition, the ACC is vulnerable to 
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hypercortisolism (Cerqueira et al., 2005). Reduced grey matter volume and reduced metabolic 
activity of the ACC has been reported in positron emission tomography (PET) and magnetic 
resonance imaging (MRI) studies of MDD subjects (Drevets et al., 1997; Coryell et al., 2005). 
Dysregulation of GABAergic neurotransmission in the ACC has been thought to be involved in 
the molecular neuropathogenesis of mood dysregulation (Thompson et al., 2009; Tripp et al., 
2011; Tripp et al., 2012; Zhao et al., 2012). Moreover, reduced glutamine (the molecular 
precursor of GABA and glutamate) is also found in the ACC (Walter et al., 2009). Furthermore, 
functional imaging studies have documented aberrant neuronal activation of the ACC in 
depressed subjects (Bremner et al., 2004; Alexopoulos et al., 2008; Matthews et al., 2008).   
1.1.7 Summary of dissertation research  
In order to improve medical treatment of affective spectrum disorders, it is necessary to 
understand the pathophysiology that underlies its core feature - mood dysregulation. The goal of 
this dissertation is to improve our understanding of the neural mechanisms underlying mood 
regulation with a focus on SST and SST-containing interneurons. We first reviewed what is 
known about the SST system in the central nervous system and SST deficits in the context of 
neurological disorders (Chapter 2). Based on known functions of SST and SST neurons in the 
brain and pathology of SST in neurological disorders, we tested our overarching hypothesis that 
SST deficits play a causal role in mood dysregulation (Chapters 4-6). We first collected 
behavioral, molecular, and neuroendocrine data from mice with low SST (Chapter 3), and found 
that compared to wild-type mice, mice lacking SST showed increased emotionality and altered 
BDNF-GABA signaling in the cingulate cortex.  A known physiological function of SST is 
neuroendocrine modulation. Accordingly, hyperactivity of the HPA axis is observed in some 
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depressed patients, and elevated stress hormones can lead to depression, although these are not 
consistent observations (Wolkowitz et al., 2009). We found elevated basal corticosterone in SST 
heterozygous mice that exhibited normal emotionality, suggesting that corticosterone is not 
sufficient to induce high emotionality associated with SST deficits (Chapter 4). Furthermore, we 
found altered protein translation control in SST neurons of the cingulate cortex from mice that 
were exposed to chronic stress; suggesting that protein homeostasis could influence selective 
vulnerability to stress. Finally, we found that enhancing protein translation during stress 
mitigated stress-related emotionality, further suggesting that protein translation control is 
involved in mood regulation (Chapter 5). The studies collectively explored the functional roles of 
SST and possible pathogenetic mechanisms of selective vulnerability of SST neurons to stress in 
mice, and provided new insights for the pathophysiological mechanisms underlying MDD in 
humans. 
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PATHOPHYSIOLOGICAL SUBSTRATE AND DRUG TARGET?  
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2.1 ABSTRACT 
Our knowledge of the pathophysiology of affect dysregulation has progressively increased, but 
the pharmacological treatments remain inadequate. Here, we summarize the current literature on 
deficits in somatostatin, an inhibitory modulatory neuropeptide, in major depression and other 
neurological disorders that also include mood disturbances. We focus on direct evidence in the 
human postmortem brain, and review rodent genetic and pharmacological studies probing the 
role of the somatostatin system in relation to mood. We also briefly go over pharmacological 
developments targeting the somatostatin system in peripheral organs and discuss the challenges 
of targeting the brain somatostatin system. Finally, the fact that somatostatin deficits are 
frequently observed across neurological disorders suggests a selective cellular vulnerability of 
somatostatin-expressing neurons. Potential cell intrinsic factors mediating those changes are 
discussed, including nitric oxide induced oxidative stress, mitochondrial dysfunction, high 
inflammatory response, high demand for neurotrophic environment, and overall aging processes. 
Together, based on the co-localization of somatostatin with GABA, its presence in dendritic-
targeting GABA neuron subtypes, and its temporal-specific function, we discuss the possibility 
that deficits in somatostatin play a central role in cortical local inhibitory circuit deficits leading 
to abnormal corticolimbic network activity and clinical mood symptoms across neurological 
disorders.  
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2.2 INTRODUCTION 
Mood disturbances are commonly observed in many neurological disorders. The chronic, 
recurrent and long duration of mood disturbances not only place an enormous emotional and 
financial burden on patients, but also on their families and society. Nearly 10% of all primary 
care office visits are depression-related (Stafford et al., 2000), but only 30% of patients with 
mood disturbances achieve remission with initial treatment (Trivedi et al., 2006). Somatostatin is 
a peptide expressed in multiple organs. In the brain, somatostatin (also known as somatotrophin 
release inhibiting factor and often abbreviated as SST, SRIF, or SOM) acts as a modulatory and 
inhibitory neuropeptide that is co-localized with gamma-aminobutyric acid (GABA), and that is 
involved in regulating multiple aspects of physiological and behavioral stress responses, 
including inhibition of hypothalamic hormone release, amygdala central nucleus output, and 
cortical local circuit integration of sensory input. Research advances over the past three decades 
suggests a critical role for somatostatin in the pathophysiology of mood disorders, and potential 
new therapeutic strategies. Several recent reviews have summarized the role of the somatostatin 
system, including in receptor subtypes (Patel, 1999; Csaba & Dournaud, 2001), pharmacological 
developments (Neggers & van der Lely, 2009), and during normal and pathological aging (Patel, 
1999; Viollet et al., 2008; Martel et al., 2012). This article highlights current findings on the 
functional roles of somatostatin in local neuronal circuits, and reviews somatostatin deficits 
across neurological disorders, including neuropsychiatric disorders [e.g., MDD, bipolar disorder, 
schizophrenia], and neurodegenerative disorders [e.g., Parkinson's, Alzheimer’s disease, 
Huntington’s diseases] (Table 1). This raises interesting questions, including first; whether the 
somatostatin deficits observed in neurological disorders represent common, distinct, or partly 
overlapping mechanisms of symptoms across disorders and, second, what may be the causes and 
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biological mechanisms underlying the selective neuronal vulnerability of somatostatin-
expressing neurons. In addition, we review somatostatin findings associated with affect 
regulation at the genetic, cellular, and pharmacological levels in animal studies.  So far, these 
findings suggest that somatostatin deficits across different brain systems and diseases may play a 
central role in the affective symptom dimension rather than non-specific signals in neurological 
disorders (Figure 1). As somatostatin itself is not an ideal drug target, including for 
antidepressant effect, we suggest that further studies characterizing the intrinsic properties and 
biological vulnerabilities of somatostatin-expressing neurons, may identify novel targets with 
implications for understanding the function of local cell circuits and brain regions underlying 
affective symptoms across several neurological disorders. 
2.3 LOW SOMATOSTATIN IN NEUROPSYCHIATRIC AND 
NEURODEGENERATIVE DISORDERS 
2.3.1 Major depressive disorder 
 MDD patients show decreased somatostatin levels in the cerebrospinal fluid (CSF) (Agren & 
Lundqvist, 1984; Molchan et al., 1991; Kling et al., 1993), and transiently decreased CSF 
somatostatin which normalize with recovery in MDD (Rubinow et al., 1985; Post et al., 1988). 
Evidence for low levels of CSF somatostatin was found to correlate significantly with elevated 
urinary cortisol in MDD patients (Molchan et al., 1993). This is consistent with the altered HPA 
axis function described in some depressed patients (Holsboer, 2000). The route and 
characterization, however, from CSF somatostatin to MDD pathophysiology is not direct, 
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potentially due to a paucity of information on factors regulating CSF somatostatin, and to 
inconclusive somatostatin/HPA axis studies in MDD patients. Hence, despite these early 
findings, interest in somatostatin in mood disorders declined over time. 
Human post-mortem studies from our group have described region-specific somatostatin 
deficits in MDD patients, including a down-regulation of somatostatin gene expression in the 
dorsolateral prefrontal cortex (dlPFC), subgenual anterior cingulate cortex (sgACC), and 
amygdala (Sibille et al., 2011; Tripp et al., 2011; Guilloux et al., 2012; Tripp et al., 2012). In 
addition, two peptides co-localized with somatostatin, neuropeptide Y and cortistatin, are both 
significantly down-regulated in MDD patients (Tripp et al., 2011; Tripp et al., 2012).These three 
neuropeptides (somatostatin, neuropeptide Y, and cortistatin) are markers of GABAergic neurons 
that specifically target the dendritic compartment of pyramidal cells (de Lecea et al., 1997; 
Viollet et al., 2008), and that are essential in gating incoming sensory information. Other types 
of GABAergic cell markers, such as parvalbumin and cholecystokinin, are mostly not affected 
by MDD [although see (Tripp et al., 2012)]. Interestingly, these somatostatin deficits were 
systematically more robust in female subjects across cohorts and regions (Sibille et al., 2011; 
Tripp et al., 2011; Guilloux et al., 2012; Tripp et al., 2012), consistent with the female 
heightened vulnerability to develop MDD, and suggesting that low somatostatin may represent a 
molecular correlate of sexual dimorphism in vulnerability to affect dysregulation. Notably, these 
findings are also consistent with earlier postmortem studies showing reduced calbindin-positive 
cell numbers in MDD (Rajkowska et al., 2007; Maciag et al., 2010), as somatostatin is mostly 
expressed in a subgroup of calbindin-positive cells [reviewed in (Viollet et al., 2008)]. 
Converging evidence from down-regulation of somatostatin co-localized GABA markers in 
MDD across multiple human post-mortem studies suggests that this particular GABA 
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subpopulation in the forebrain is selectively vulnerable, among other subtypes of GABA 
neurons. Furthermore, these local cell circuit-based findings introduce a new role for 
somatostatin in depression, which is distinct from its previously investigated role in the 
regulation of the HPA axis (Rubinow et al., 1983; Molchan et al., 1993; Weckbecker et al., 
2003). 
2.3.2 Other neuropsychiatric disorders 
Schizophrenia is a neuropsychiatric disorder characterized by positive (e.g., hallucination), 
negative (e.g., emotional blunting, apathy) and cognitive symptoms. Somatostatin deficits in 
schizophrenia are demonstrated by a reduction of CSF somatostatin (Bissette et al., 1986; 
Reinikainen et al., 1990), decreased somatostatin gene expression in the dlPFC (Morris et al., 
2008; Guillozet-Bongaarts et al., 2013), and decreased number and density of somatostatin-
expressing neurons in the hippocampus (Konradi et al., 2011a), caudal entorhinal cortex and 
parasubiculum (Wang et al., 2011).  
Changes in somatostatin are also identified in bipolar disorder, which is clinically 
characterized by fluctuating mood. Studies in subjects with bipolar disorder indicate decreases in 
somatostatin cellular density in the caudal entorhinal cortex and parasubiculum (Wang et al., 
2011), number of somatostatin-expressing neurons in the hippocampus (Konradi et al., 2011b), 
somatostatin gene expression in the dlPFC [trend level; (Sibille et al., 2011)] and hippocampus 
(Konradi et al., 2011b). In addition, patients with bipolar disorder show elevated CSF 
somatostatin during manic states (Sharma et al., 1995). 
 14 
2.3.3 Neurodegenerative disorders 
Alzheimer’s disease is a neurodegenerative disease with neuropsychiatric symptoms (Bungener 
et al., 1996). Decreased CSF somatostatin (Bissette et al., 1986; Tamminga et al., 1987) and 
decreased somatostatin immune-reactivity across cortical and subcortical regions is reported in 
subjects with Alzheimer’s disease, including temporal cortex, frontal cortex, and hippocampus 
(Davies et al., 1980; Rossor et al., 1980; Davies & Terry, 1981; Candy et al., 1985; Dournaud et 
al., 1994).  
Depression is a common comorbid symptom in Parkinson's disease and predicts greater 
disability at any assessment point (Aarsland et al., 1999). Decreased CSF somatostatin, 
decreased somatostatin immune-reactivity, and binding sites are also observed in the temporal 
cortex and frontal cortex of patients with Parkinson’s disease (Beal et al., 1986; Epelbaum et al., 
1988). Notably, reduced CSF somatostatin in Parkinson's disease appears to be irreversibly 
present at the onset of symptoms (Dupont et al., 1982). 
2.4 REDUCED SOMATOSTATIN AND LOW MOOD? 
2.4.1 Introduction 
The evidence outlined in this review provides only a glimpse of the potential full range of 
somatostatin deficits across neurological disorders, as multiple other brain regions and disease 
categories await further characterization (Table 1). Taken together, the cumulative evidence 
demonstrates that somatostatin deficits are common neurochemical and molecular features in 
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individuals with neurological disorders, regardless of their categorical diagnosis. While 
somatostatin studies of cell number and gene expression in human postmortem brains suggest a 
specific alteration of somatostatin-positive neurons across neurological disorders, it is possible 
that changes and dys-synchronization of additional components of local neuronal circuits 
contributes to a common symptom dimension, which we speculate includes low affect and mood 
dysregulation. Hence, this review is not comprehensive, but rather, highlights the recent findings 
in brain somatostatin signaling and the potential role of somatostatin deficits in affect 
dysregulation for integrating categorical models of mood symptoms into a dimensional model 
across neurological disorders.  
 
Table 1. Low somatostatin in human neurological disorders  
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2.5 SOMATOSTATIN: GENES, NEURONS AND PHARMACOLOGY 
2.5.1 Somatostatin signaling 
Somatostatin is a modulatory neuropeptide that synergizes with GABA-mediated inhibition, and 
that specifically targets the distal dendritic compartment of pyramidal neurons in cortical 
microcircuits (Kawaguchi & Kubota, 1997; Gentet et al., 2012). Somatostatin inhibits release of 
numerous hormones from the hypothalamus, including CRH (Wang et al., 1987; Patel, 1999). 
The somatostatin gene product is composed of 14 or 28 amino-acid residues. Both forms of 
somatostatin, somatostatin-14 and somatostatin-28, are generated by tissue-specific post-
translational processing of 116 amino-acid pre-pro-somatostatin peptide (Warren & Shields, 
1984; Tostivint et al., 2008).  Somatostatin-14 is predominantly produced in the central nervous 
system (CNS) but also in many peripheral organs (Epelbaum, 1986). Somatostatin-28 is mainly 
synthesized along the gastrointestinal tract (Fitz-Patrick & Patel, 1981). The 5’-upstream 
sequence of the somatostatin gene contains cyclic-AMP response element (CRE) (Montminy et 
al., 1986), making its expression activity-dependent. Thus, somatostatin expression is 
preferentially altered by various stressors, such as seizures (Vezzani & Hoyer, 1999; Tallent & 
Qiu, 2008) and electrical foot shock (Ponomarev et al., 2010). Moreover, mice with conditional 
homozygous and constitutive heterozygous brain-derived neurotrophic factor (Bdnf) knockout or 
disruption of exon IV-expressing Bdnf transcripts show decreased somatostatin gene expression 
(Glorioso et al., 2006; Martinowich et al., 2011; Guilloux et al., 2012), demonstrating that the 
levels of somatostatin expression depend on Bdnf function. However, the molecular mechanisms 
by which this neurotrophic factor controls somatostatin and somatostatin-expressing neurons are 
still unknown. 
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Somatostatin, cortistatin and their receptors are closely intertwined systems [(de Lecea et 
al., 1996; de Lecea et al., 1997), reviewed in (Spier & de Lecea, 2000; de Lecea, 2008)]. Sharing 
high structural homology with somatostatin, cortistatin binds to all somatostatin receptor 
subtypes and is known to be regulated by exon IV-expressing Bdnf transcripts (Martinowich et 
al., 2011). However, distinct from somatostatin, cortistatin binds to additional receptors (e.g., 
growth hormone secretagogue receptor 1a and Mas-related gene X2 receptor) (Robas et al., 
2003; Siehler et al., 2008) and has different physiological properties (e.g., activation of cation 
selective currents not responsive to somatostatin) (Spier & de Lecea, 2000), suggesting that 
somatostatin and cortistatin may both contribute to affect regulation in an integrated, yet 
differential mode. The intracellular pathway of somatostatin signaling coupled to all five 
somatostatin receptors subtypes (Sst1-5) is through the activation of inhibitory G protein (Gi) and 
the following inhibition of adenylyl cyclase, leading to reduction of cAMP levels, activation of 
phosphotyrosine phosphatases, and modulation of mitogen-activated protein kinases and 
phospholipase C (Koch & Schonbrunn, 1984; Koch et al., 1988). Sst1-5 present different patterns 
of coexpression in the brain (Kluxen et al., 1992; Moller et al., 2003) [reviewed in (Martel et al., 
2012)].  
Sst1 is found in retina, basal ganglia and hypothalamus, Sst2 is highly abundant in 
several telencephalic structures (neocortex, hippocampus, and amygdala), 
Sst3  immunoreactivity has only been described in neuronal cilia (Schulz et al., 2000), Sst4 is 
expressed in olfactory bulb, cerebral cortex and CA1 region of the hippocampus (Schreff et al., 
2000), and expression of Sst5 has been detected in cerebral cortex, hippocampus, amygdala, 
preoptic area, and hypothalamus (Stroh et al., 1999; Strowski et al., 2003; Olias et al., 
2004). Interestingly, when co-expressed in the same cells, Sst5 influences Sst2 internalization 
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and trafficking and modulates cellular desensitization to the effects of somatostatin-14 (Sharif et 
al., 2007), suggesting that the precise actions of somatostatin depend on the specific interaction 
of the Sst1-5 receptors expressed locally in each brain region. 
2.5.2 Genetic polymorphisms in the somatostatin system 
The relatively high degree of amino acid conservation across species indicates that somatostatin-
related genes have been highly constrained during evolution (Patel, 1999; Olias et al., 2004). 
Accordingly, there are currently very few reports linking somatostatin gene polymorphisms with 
neurological disorders. A primate-specific single nucleotide polymorphism (SNP) in the human 
somatostatin gene [C/T polymorphism (rs4988514)] is associated with increased risk in 
Alzheimer's disease progression and additive effect with the APOE epsilon4 allele(Vepsalainen 
et al., 2007; Xue et al., 2009), although this was not confirmed in larger GWAS studies 
(Hollingworth et al., 2011; Guerreiro et al., 2013). Leu48Met and Pro335Leu SNPs in the SST5 
gene are of potential significance to patients with bipolar disorder (Nyegaard et al., 2002), but no 
associations of SST5 SNPs are found in patients with autism (Lauritsen et al., 2003). The paucity 
of associations with somatostatin gene variants is surprising and may reflect either strong 
negative selection against genetic variations in this gene, or alternatively, dilution of signal due 
to heterogeneity of Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV-based 
cohorts in genetic association studies. So, dimensional phenotypes, as defined by clusters of 
mood symptoms, which are closer to gene functions may have implications for future genetic 
studies of somatostatin and other genes. 
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2.5.3 Somatostatin-expressing neurons: diversity and roles 
GABA neurons are a diverse group of inhibitory cells which co-release neuropeptides in order to 
support a fine-tuning of neuronal signaling and architecture. The local inhibitory circuits provide 
spatiotemporal control of information processing through at least 20 subtypes of cortical GABA 
neurons, which are based on their expression of different calcium binding proteins and 
neuropeptides, localization, targeting, and differential electrophysiological properties. Recent 
detailed reviews on GABA neuron subpopulations have been published (Csaba & Dournaud, 
2001; Di Cristo et al., 2004; Markram et al., 2004; Tan et al., 2008; Fishell & Rudy, 2011; 
Gentet et al., 2012; DeFelipe et al., 2013; Le Magueresse & Monyer, 2013). Approximately 20-
30 % of GABA neurons in the mouse somatosensory cortex express somatostatin (Lee et al., 
2010; Rudy et al., 2011), and 40-50 % of GABA neurons contain parvalbumin without 
overlapping with somatostatin in the frontal cortex, primary somatosensory cortex and visual 
cortex of mouse (Gonchar et al., 2007; Xu et al., 2010) and the visual cortex of rat (Gonchar & 
Burkhalter, 1997).  
Recent reports focusing on patterns of cortical neuronal connectivity show that 
somatostatin-expressing interneurons mediate the firing of pyramidal neurons with a fine level of 
specificity among cortical layers. Integrating optogenetic and electrophysiology approaches, 
mouse somatostatin-expressing interneurons in layer 2/3 of the somatosensory cortex provide a 
tonic inhibition to the distal dendrites of excitatory pyramidal neurons by sharpening selectivity 
during periods of quiet wakefulness, which may contribute to synchronized firing in cortical 
networks and sensorimotor integration (Gentet et al., 2012). Interestingly, in mouse 
somatosensory cortex, somatostatin-expressing interneurons show a spatially precise 
connectivity with pyramidal neurons through direct targeting in layers 2/3 or indirectly through 
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inhibition of local parvalbumin interneurons in layer 4 (Xu et al., 2013). Moreover, in layers 2/3 
of the mouse prefrontal cortex, somatostatin-expressing interneurons compartmentalizes 
inhibitions of calcium signaling to spine heads, not shafts, suggesting that dendrite-targeting 
inhibition though somatostatin-expressing interneurons may contribute to downstream cellular 
processes such as synaptic plasticity (Chiu et al., 2013). In mouse visual cortex, somatostatin-
expressing interneurons are found to mediate response levels of specific subsets of pyramidal 
neurons whereas parvalbumin-expressing neurons alter response gain (Wilson et al., 2012). 
Parvalbumin-expressing neurons receive excitatory input from the thalamus and make strong 
synapses on the soma and axons of their target cells (Kawaguchi & Kubota, 1997) to control 
spike timing of the output neurons. In contrast, somatostatin-expressing neurons mostly do not 
receive input from thalamus (Beierlein et al., 2003; Cruikshank et al., 2010) and are instead 
activated through feed-forward mechanisms by activated pyramidal cells. Somatostatin-
expressing interneurons preferentially target distal dendrites of pyramidal neurons in layer 2/3 to 
modulate the processing of incoming sensory information before it is integrated at the soma (Di 
Cristo et al., 2004; Markram et al., 2004; Tan et al., 2008; Murayama et al., 2009; Xu et al., 
2013). Hence, the distinct GABAergic and prototypical inhibitory populations, expressing either 
parvalbumin or somatostatin, shape the spatiotemporal control of multiple post-synaptic 
potentials in cortical local circuits, and provide a framework to investigate the role of inhibitory 
circuits in physiology and pathology.  
2.5.4 Genetic approaches to investigate the somatostatin system  
Mice mutant for somatostatin were created by deleting the coding region of the pre-pro-
somatostatin (the last ten codons of the first exon) (Zeyda et al., 2001). Somatostatin knockout 
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(KO; SstKO) mice show intact motor coordination and motor learning, but have a significant 
impairment in motor learning as demands of motor coordination are increased. Overall, a 
detailed analysis demonstrated that SstKO mice are healthy, fertile, and show no overt behavioral 
phenotypes, including anxiety-like behavior in the open-field and fear conditioning tests. 
Notably, SstKO mice display high basal plasma levels of corticosterone and growth hormone 
(Zeyda et al., 2001), confirming somatostatin-mediated inhibition of HPA axis function. 
Similarly, mice lacking individual Sst1-5 receptors have been tested in numerous biological 
functions. Of these, Sst2 emerged as the primary receptor of interest (Zeyda & 
Hochgeschwender, 2008), and Sst2
KO mice display increased anxiety-like behavior in the 
elevated plus maze and open field, increased immobility in the forced swim test, decreased 
locomotion coupled with an increase of pituitary adrenocorticotropic hormone release instead of 
growth hormone (Viollet et al., 2000). In line with the observed changes in Sst2
KO mice, acute 
predator stress in rats led to up-regulated Sst2 gene expression in the amygdala and ACC, shown 
correlated with Fos expression in the amygdala (Nanda et al., 2008). As the product of a 
different gene, cortistatin shares a high structural and functional similarity with somatostatin-14 
(de Lecea et al., 1996; de Lecea et al., 1997). Notably, compared with the weak inhibitory effects 
of somatostatin on the basal release of CRH from rat hypothalamus and hippocampus, cortistatin 
exhibits strong inhibition of the expression and release of basal CRH (Tringali et al., 2012). 
These findings suggest that Sst2 may regulate affective phenotypes and HPA axis responses both 
through somatostatin and cortistatin. Given the limitations of human studies, SstKO mice provide 
an opportunity to explore the causal role of somatostatin in affect dysregulation and the 
underlying neural mechanisms. Such insights, however, will require systematic behavioral 
characterization with fine spatial and temporal resolution by including female cohorts and 
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region-specific manipulation at different developmental stages. Based on the published studies to 
date, it is still unclear whether these mutants recapitulate behavioral features of mood disorders. 
Knowing the effects of somatostatin signaling on neuroendocrine regulation, future studies need 
to assess the molecular and cellular systems that somatostatin mutations converge upon, and 
where the exact neural circuits are affected. Moreover, combining genetic and environmental 
factors in animal models is critical to enhance the accuracy of disease modeling and translational 
efforts. For example, acute or chronic exposure to stress or to stress hormones may capture how 
such etiological factors determine the vulnerability to develop high behavioral emotionality, in 
contrast to baseline behavioral testing. In addition, mood disorder-related sex differences are 
observed in community-based epidemiological studies, where the factor of seeking treatment is 
removed (Kornstein et al., 2000; Leach et al., 2008) and findings of low somatostatin in the 
amygdala appear more robust in postmortem studies of female MDD subjects (Tripp et al., 
2012), suggesting that gender/sex may represent a biological predisposing factor, or at least a 
moderating factor, in the intrinsic vulnerability of the somatostatin system. 
Although many mood disorders emerge during adolescence (Paus et al., 2008), 
behavioral abnormalities including affect dysregulation are often heritable and apparent before 
diagnostic criteria are met (McGuffin et al., 2003; Geller et al., 2006). It is unclear when 
somatostatin deficits occur and potentially begin to contribute to the formation of affective 
symptoms. Tracking somatostatin system using new anatomic techniques with refined cellular 
definition, from Brainbow (Livet et al., 2007) to CLARITY(Chung et al., 2013) and SeeDB (Ke 
et al., 2013), across different developmental stages may help identify age-dependent neural 
architecture and disease mechanisms related to somatostatin function.  
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2.5.5 Somatostatin analog development and pharmacological studies 
As native somatostatin peptides have a very short half-life time (approximate 1-3 minutes) 
(Sheppard et al., 1979), long-acting and highly potent somatostatin analogues are currently 
available for the treatment of acromegaly and neuroendocrine tumors, including octreotide (long-
acting; LAR-OCT) (Bauer et al., 1982) and Lanreotide (slow release or autogel) (Bevan, 2005; 
Molitch, 2008). Compared to somatostatin, pharmacological tools of the five somatostatin 
receptor subtypes have lagged behind, partly due to the lack of high-affinity antagonists. 
In addition, several novel somatostatin therapy models are available: 1) Universal 
somatostatin (Schmid & Schoeffter, 2004): a somatostatin molecular analog with high binding 
affinity to all or most human somatostatin receptors. An example is SOM230, which interacts 
with Sst1,2,3,5 and particularly potent at Sst5 compared with LAR-OCT; 2) Chimeric 
somatostatin/dopamine molecule (Saveanu et al., 2002; Pivonello et al., 2005): a somatostatin 
and dopamine hybrid agonist, based on reports that dopamine and somatostatin receptors can 
hetero-oligomerize to enhance functional responses (Rocheville et al., 2000). An example is 
BIM-23A760, which accelerates the suppression of growth hormone and adrenocorticotropic 
hormone by the interaction with Sst2 and Drd2 simultaneously; 3) Chimeric-somatostatin 
vaccinations (Haffer, 2012): a fusion protein expressing chloramphenicol acetyl transferase 
protein and somatostatin. Two somatostatin vaccinations, JH17 and JH18, can effectively reduce 
weight gain and reduce final body weight percentage of normal, non-obese mice and mice with 
diet-induced obesity via the intra-peritoneal route; 4) Non-peptide antagonists, such as SRA880 
(Sst1 selective), ACQ090 (Sst3 selective) and Sst4 selective β peptide agonists (Rivier et al., 2003; 
Hoyer et al., 2004). Despite this extensive list, the practical use of somatostatin in the brain is 
hampered by the multiple effects of the peptide, by the need for small molecules targeting 
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specific, high affinity receptors on the target cells in specific brain regions, and by the need for 
feasible routes of administration that lead to fast delivery into the brain. 
The potential for using somatostatin analogues as treatment in the CNS is emerging for 
treatment of epilepsy (Vezzani & Hoyer, 1999; Tallent & Qiu, 2008), pain (Mollenholt et al., 
1994; Taura et al., 1994), headaches (Sicuteri et al., 1984; Kapicioglu et al., 1997); potential use 
for treatment of mood disorders is suggested by reversal of emotion-like behaviors in rodent 
models. Several pharmacological studies support a role of somatostatin in affect regulation. 
Intra-ventricular administration of somatostatin in rats produces anxiolytic- and antidepressant-
like behaviors in the elevated plus-maze and forced swim tests, and a neurophysiological 
signature of anxiolytic drugs (e.g., reduction of theta frequency and theta frequency curve slope) 
(Engin et al., 2008). Mice with intra-amygdalar and intra-septal microinfusions of somatostatin-
14 and somatostatin-28 display reduced anxiety-like behavior in the elevated plus-maze and 
shock-probe tests (Yeung et al., 2011). Moreover, anxiolytic effects in the elevated plus-maze 
test are described after intra-cerebroventricular infusions of a selective Sst2 receptor agonist, but 
not after infusions of the other four receptor agonists; antidepressant-like effects in the forced 
swim test are observed following infusions of either Sst2 or Sst3 agonists (Engin & Treit, 2009). 
Another agent to enhance somatostatin functioning, SRA880 (an antagonist of auto-receptor 
Sst1), synergizes with imipramine in causing antidepressant-like effects in the tail suspension test 
and increases Bdnf mRNA expression in the mouse cerebral cortex (Nilsson et al., 2012). 
2.5.6 Effects of antidepressants on somatostatin in the CNS 
Significant efforts have been directed toward the characterization of the downstream targets of 
antidepressant treatment, with a focus on somatostatin. A recent study demonstrates that chronic 
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imipramine treatment increases somatostatin expression in mouse hypothalamus (Nilsson et al., 
2012). However, there is inconsistency regarding the effect of chronic citalopram treatment on 
somatostatin levels in rats (Kakigi et al., 1992; Prosperini et al., 1997; Pallis et al., 2006; Pallis 
et al., 2009). Repeated administration of imipramine, maprotiline, mianserin, carbamazepine or 
zotepine has no effect on somatostatin levels in various brain regions of rats (Weiss et al., 1987; 
Kakigi et al., 1992).  
While some somatostatin receptors seem to exert anxiolytic or antidepressant-like effects, 
there is no direct evidence supporting somatostatin receptors as downstream targets of current 
antidepressants. Together, these findings suggest that somatostatin levels are mostly unchanged 
by antidepressants. It is unclear whether somatostatin, GABA, or GABA functioning in 
somatostatin-expressing interneurons may be the real mediators or antidepressant targets. Future 
studies are needed to determine the involvement of somatostatin receptors and associated 
intracellular signaling pathways in the therapeutic effects of antidepressants, or whether 
somatostatin effects are independent of current antidepressant modalities.  
2.6 POTENTIAL MECHANISMS OF SELECTIVE VULNERABILITY OF 
SOMATOSTATIN-EXPRESSING INTERNEURONS 
It is possible that low somatostatin in diseases acts as a biomarker for deregulated function of 
somatostatin-expressing neurons. As such, it is essential to identify upstream factors responsible 
for the dysfunction of somatostatin-expressing interneurons in neurological diseases. We 
speculate that intrinsic cellular properties in somatostatin-expressing neurons may determine 
their selective vulnerability to various insults. Pathways underlying this high vulnerability may 
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include high intrinsic oxidative stress related to mitochondria, high sensitivity to inflammation, 
high dependence on neurotrophic environment, and cellular developmental and aging processes. 
These canonical pathways might provide novel cell-based perspectives in the treatment of 
affected somatostatin-expressing cells across neurological disorders. 
2.6.1 Oxidative stress and mitochondrial dysfunctions 
Oxidative stress produced by mitochondria during respiration is a common pathogenic 
mechanism implicated in neurological disorders (Sorce & Krause, 2009; Stefanescu & Ciobica, 
2012). Depressed states in mood disorders are associated with decreased brain energy generation 
(Baxter et al., 1985; Baxter et al., 1989). Dysfunctional mitochondria together with the oxidative 
stress accumulation has been proposed to synergistically contribute to the neuro-endangerment 
processes underlying depression (Gardner et al., 2003; Burnett et al., 2005) and 
neurodegenerative diseases (Lin & Beal, 2006; Mancuso et al., 2007; Petrozzi et al., 2007). 
Similarly, high baseline oxidative stress could be an intrinsic characteristic of vulnerable 
neuronal populations. Notably, neuronal nitric oxide synthase (nNOS) and NADPH diaphorase 
(NADPHd), two enzymes that produce reactive oxidative species, are extensively and almost 
exclusively co-localized with somatostatin and neuropeptide Y (Dun et al., 1994; Figueredo-
Cardenas et al., 1996; Jaglin et al., 2012), hence providing a neurochemical basis for high 
susceptibility of somatostatin-expressing neurons to generate oxidative stress in response to 
pathophysiological insults. 
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2.6.2 High dependence on neurotrophic environment 
BDNF and its receptor neurotrophic tyrosine kinase receptor type 2 (TrkB) have been implicated 
in mood disorders (Guilloux et al., 2012; Tripp et al., 2012). BDNF-TrkB signaling is one of the 
key mediators for maintaining normal somatostatin gene expression (Glorioso et al., 2006; 
Martinowich et al., 2011).Progressively decreasing BDNF-TrkB signaling in patients with mood 
disturbances may directly impact the biology of somatostatin-expressing neurons, resulting in 
somatostatin deficits. In addition, Bdnf-TrkB signaling itself is vulnerable to increased 
inflammation (Goshen et al., 2008; Koo & Duman, 2008; Song & Wang, 2011) and high 
glucocorticoid insults (Hodes et al., 2012). Mild oxidative stress inhibits tyrosine phosphatases 
activity (Barrett et al., 2005), potentially leading to impaired TrkB downstream signaling. 
Cortistatin and neuropeptide Y expression partly overlaps with the somatostatin neuron 
population in rodents (Figueredo-Cardenas et al., 1996; de Lecea et al., 1997; Xu et al., 2010). 
Comparing the profile of gene changes between subjects with MDD and mice with genetically-
altered Bdnf signaling suggest that the reduced somatostatin, neuropeptide Y and cortistatin are 
partly downstream from a combination of reduced constitutive and activity-dependent Bdnf 
signaling (Guilloux et al., 2012). In contrast, markers for other GABA neuron subtypes targeting 
the perisomatic area region cell body and axon initial segment of pyramidal neurons (i.e., 
cholecystokinin and calretinin), appear to be independent of BDNF signaling and unaffected in 
MDD patients (Guilloux et al., 2012; Tripp et al., 2012). Hence, it is possible that the 
somatostatin-specific cellular function and vulnerability are partly mediated by BDNF-TrkB 
signaling during both physiological and pathological processes of affect regulation. 
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2.6.3 Inflammation and cellular aging  
Inflammation has been implicated as a contributing factor in the onset and progression of many 
neurological disorders (Di Filippo et al., 2008). Mood disturbances are associated with an 
activated inflammatory response system (Padmos et al., 2008; Miller et al., 2009), including 
increased levels of peripheral interleukins and tumor necrosis factor-alpha in MDD patients 
(Kaestner et al., 2005; Howren et al., 2009; Dowlati et al., 2010; Maes, 2011). Inflammatory 
illnesses are associated with more depressive episodes (Celik et al., 2010; Maes et al., 2012), 
suggesting that prior depression may sensitize inflammatory responses. Patients treated with 
inflammatory cytokines, such as interferon-α, are at greater risk of developing depressive 
episodes (Castera et al., 2006; Lotrich et al., 2007). Somatostatin released from sensory nerves 
and somatostatin receptors on peripheral blood mononuclear cells play a crucial role in anti-
inflammation through inhibition of pro-inflammatory peptide release (Szolcsanyi et al., 1998; 
Kurnatowska & Pawlikowski, 2000; Helyes et al., 2004). Rats with chronic inflammation 
induced by lipopolysaccharide show decreased hippocampal somatostatin expression (Gavilan et 
al., 2007). It is possible that there is crosstalk among peripheral inflammation, somatostatin 
function, and central effects of somatostatin-expressing neurons. Hence, decreasing somatostatin 
expression due to cellular impairment in the progress of neurological diseases may further 
enhance inflammation in a vicious cycle, leading to exacerbated cellular vulnerability of 
somatostatin-expressing neurons.  
Aging is associated with a considerable increase in an activated, pro-inflammatory state 
(Wei et al., 1992; Bruunsgaard & Pedersen, 2003), a decline in circulating levels of Bdnf 
(Erickson et al., 2010), and increased oxidative damage (Sohal & Weindruch, 1996). 
Somatostatin expression is significantly decreased with age in human cortical regions, but 
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parvalbumin expression is not altered by age (Erraji-Benchekroun et al., 2005; Glorioso et al., 
2011). Similarly, the number of hippocampal somatostatin-expressing interneurons decreases in 
aged rats, but the number of parvalbumin-expressing neurons remains the same (Vela et al., 
2003). Somatostatin and IL-1β mRNA expression are negatively correlated in aged hippocampus 
of rats (Gavilan et al., 2007). Comparing the effects of aging on somatostatin expression in the 
sgACC, an accelerated reduction is found in patients with major depression compared to normal 
aging subjects (Tripp et al., 2012), suggesting a pattern resulting in an early aging phenomenon 
which we have speculated may be synergistically induced by normal age-related changes and 
depression-related pathological change (Douillard-Guilloux et al., 2013). 
2.7 CONCLUSION 
Here we have focused on somatostatin, a GABA marker, down-regulated in MDD, 
schizophrenia, bipolar disorder, and neurodegenerative diseases. Exploring cross-disease 
molecular (somatostatin) and cellular units (somatostatin-expressing interneurons) pathological 
findings suggests a dimensional pathological phenotype that is specific to the somatostatin 
gene/cell biological entity rather than to categorical brain disorders. Based on these results we 
speculate that a common mechanism affecting somatostatin and somatostatin-expressing neurons 
may impact information processing by the local inhibitory cell circuit in cortical regions (Figure 
1). Clarifying the role of somatostatin and its regulation of GABA inhibition in affect regulation 
would provide new strategies for predicting, delaying, and treating neurological diseases with 
mood disturbances. A number of questions remain. For example, are the prevalent somatostatin 
deficits seen in multiple diseases reflected in a common symptom dimension, such as low mood, 
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across neurological diseases? What are the critical events that determine the vulnerability of 
somatostatin-expressing neurons? And what are the pathogenic mechanisms that mediate the 
observed disease-related molecular and cellular phenotypes? One possibility is that 
inflammation, oxidative stress, aging, and reduced neurotrophic support may all converge to 
affect somatostatin-expressing neurons. Targeting these pathways may exert neuro-protective 
effects on somatostatin-expressing neurons, as a potential therapeutic approach with implications 
for several neuropsychiatric disorders and neurodegenerative diseases. 
 
Figure 1. Schematic of somatostatin signaling, pathological regulators and biological functions relevant to 
affect regulation.  
Somatostatin pathway activity is responsive to (left panel), and regulates (right panel), several biological events, and 
molecular and cellular properties that have been linked to mood disturbances. Somatostatin and somatostatin-
expressing interneurons are key conduits for somatostatin signaling regulation and output. NPY, neuropeptide Y; 
PYR, pyramidal neuron; PV, parvalbumin. 
 
 
 31 
3.0  CAUSAL ROLE OF SOMATOSTATIN IN MOOD REGULATION 
3.1 ABSTRACT 
SST deficits appear to be a common feature of depression and other neurological disorders with 
mood dysregulation. However, whether SST deficits play a causal role in mood dysregulation is 
not clear. Consequently, in this study we used a battery of behavioral tests to characterize 
anxiety/depressive-like behaviors in SST knockout (SstKO) mice at baseline and after exposure to 
6 weeks of unpredictable chronic mild stress (UCMS). In addition, we explored the molecular 
phenotypes associated with mood dysregulation in mice with low SST. Under baseline 
unstressed conditions, compared to SstWT mice SstKO mice showed increased latency to begin 
eating in the novel suppressed feeding (NSF) test and elevated overall behavioral emotionality. 
After UCMS treatment, increased latency to feed in the NSF test and higher emotionality were 
found in stressed SstKO mice compared to stressed SstWT mice. In addition, when compared to 
non-stressed SstWT mice, non-stressed SstKO mice exhibited molecular changes in the cingulate 
cortex, including low expression of Cort, Bdnf, and Gad67. On the other hand, non-stressed SstHZ 
mice showed elevated Cort and reduced Bdnf expression. The compensatory upregulation of 
Cort may account for generally better preserved SST functions in SstHZ mice. Together, these 
findings support the hypothesis that SST deficits play a causal role in mood dysregulation. 
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3.2 INTRODUCTION 
Converging evidence from susceptibility genes is beginning to slowly uncover the polygenetic 
mechanisms underlying the pathophysiology of mood dysregulation. For instance, somatostatin 
(SST; also called SOM or SRIF) deficits are frequently observed in neurological disorders with 
mood disturbances, such as schizophrenia, bipolar disorder and Alzheimer’s disease (Martel et 
al., 2012; Lin & Sibille, 2013). In depression, Sst gene expression is robustly affected in the  
prefrontal cortex, cingulate cortex, and amygdala, three brain regions involved in mood 
regulation (Sibille et al., 2011; Tripp et al., 2011; Guilloux et al., 2012).  
SST is an inhibitory modulatory neuropeptide that is co-expressed with gamma-
aminobutyric acid (GABA). SST-expressing interneurons preferentially target the dendrites of 
pyramidal neurons (Hendry et al., 1984; Melchitzky & Lewis, 2008; Xu et al., 2010). Thus, it 
has been hypothesized that SST neurons regulate information input by providing spatiotemporal 
integration of postsynaptic potential in local cortical circuits (Gentet et al., 2012; DeFelipe et al., 
2013; Le Magueresse & Monyer, 2013). Biological stressors, such as seizure or electrical foot 
shock, can selectively affect SST interneurons or Sst expression (Vezzani & Hoyer, 1999; 
Ponomarev et al., 2010). Moreover, brain-derived neurotrophic factor (BDNF) signaling, a key 
pathway for the maintenance of normal Sst- and other GABA- related gene expression is reduced 
in depression (Grosse et al., 2005; Glorioso et al., 2006; Martinowich et al., 2011). MDD-related 
phenotypes may represent distal effects of these multiple genes.  
Here, we utilized elevated plus maze (EPM), open field (OF), novelty-suppressed feeding 
(NSF), and sucrose preference (SP) test in mice lacking Sst (SstKO) mice to characterize trait 
(baseline) and state (after UCMS) anxiety/depressive-like behavioral phenotypes. Z-score 
normalization was applied to summarize quantitative phenotypes in behavioral tests. In addition, 
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we utilized real-time qPCR to investigate the molecular phenotypes associated with mood 
dysregulation, including expression of Sst, Npy, Cortistatin, Gad67, Bdnf  in the cingulate cortex 
in mice with low SST. 
3.3 MATERIALS AND METHODS 
3.3.1 Animals  
By crossing with SstHZ mice, littermates of SstKO, SstHZ and SstWT were used in these studies. 
SstKO mouse line was previously generated and purchased from the Jackson Laboratory (stock 
no. 008117) (Zeyda et al., 2001).  Genotypes were identified by Polymerase Chain Reaction 
(PCR) analysis of DNA isolated from tail cuts. Cohort 1 consisted of 27 mice [18 SstWT (9 males, 
6 females), SstKO (6 males, 6 females)] and was used exclusively for the behavioral assessments. 
Accordingly, cohort 1 was tested for behavioral phenotypes in the EPM, OF, NSF, and SP at 3 
months of age, before and after stress treatment. Cohort 2 consisted of 36 mice [16 SstWT (8 
males, 11 females), 20 SstKO (8 males, 9 females)] and was used to validate behavioral 
phenotypes using the same battery of tests. Cohort 3 consisted of 48 mice (n =16 per genotype, 
8/sex), and was used to examine molecular phenotypes. The use of animals, including all 
treatments, was conducted in compliance with the NIH laboratory animal care guidelines and 
with protocols approved by the Institutional Animal Care and Use Committee of University of 
Pittsburgh. All experiments were performed with 3- to 5 month-old male and female littermates. 
All mice were cared under standard conditions (12/12-hour light/dark cycle, lights on at 07:00 h), 
22 ± 1°C, with food and water ad libitum). 
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3.3.2 Unpredictable chronic mild stress 
To receive UCMS treatment, mice were subjected to six weeks of a random schedule consisting 
of 1-3 environmental stressors per day, seven days per week (Surget et al., 2009). Stressors 
included repeated bedding change, no bedding, reduced housing space, forced bath (~2 cm of 
water in cage), wet bedding, aversive smell (exposure to fox or bobcat urine), social stress (rotate 
mice into previously occupied cages or single-housing), 45° tilted cage, and mild restraint (stay 
in 50-ml falcon tube with air hole). Weekly assessment of weight and fur was performed to 
monitor physiological progression of the UCMS syndrome. The social isolation treatment began 
from the fifth week of UCMS until the day of euthanasia. 
3.3.3 Behavior 
Anxiety/depressive-like behaviors were tested in the elevated plus maze (EPM), open field (OF), 
novelty suppressed feeding (NSF), and sucrose preference test (SP) in the following order for 
each mouse: EPM, OF, NSF, SP, separated by a minimum of 1 day. All tests were performed 
during the light phase of the circadian cycle, between 9 am and 3 pm.  
 
Elevated plus maze (EPM) 
 
 
Anxiety-like behaviors and locomotion were measured in a cross maze with two open and two 
closed arms (30 cm x 5 cm) as previously described (Sibille et al., 2000). Entries and time spent 
in the open arms were recorded for 10 min to assess anxiety-like behaviors. Total number of 
entries was assessed as an index of locomotion. 
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Open field (OF) 
Anxiety-like behaviors and locomotion were measured in a 76 x 76 cm chamber divided in 16 
even-size squares and monitored for 10 min using the Any-maze video-tracking software 
(Stoelting, Wood Dale, IL). Percentage of walking distance and time spent in the four center 
squares were assessed to evaluate anxiety-like behaviors. Total walking distance in the chamber 
was used as an index of locomotion.   
 
Novelty suppressed feeding (NSF) 
Anxiety/depressive-like behaviors were measured for 11 min in a 76 x 76 cm chamber, with a 
food pellet in the bright-lit center. The drive to overcome the aversive center was increased by 16 
hours of food deprivation before testing. The latency to start eating the food pellet was measured 
as an index of anxiety/depressive-like behaviors. Food consumption in the home cage for six 
minutes after the test was used as a measure for appetite after NSF testing and food deprivation.   
 
Sucrose preference test (SP) 
The sucrose test was performed using a two-bottle test: a bottle filled with a 2% sucrose solution 
and a bottle filled with water. Mice had free access to both water and a 2% sucrose solution 48 
hours before the test in their home cage to reduce neophobia. For the next two days, a sucrose 
preference/consumption test began in a new single-house cage for 16 h from 18:00 pm-10:00 am. 
Position of bottles was counterbalanced across the left and the right sides from test to test. 
Sucrose preference (percent) was calculated as follows: preference = [sucrose solution intake 
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(ml)/total fluid intake (ml)] × 100. Sucrose consumption was calculated as: consumption = 
[sucrose solution intake (ml)/ body weight (g)]. 
 
Z-scoring 
To investigate the consistency of behavioral performance across related tests, emotionality- or  
locomotion- related data were normalized using a Z-score methodology (Guilloux et al., 2011). 
Z-scores calculate how standard deviation (σ) and observation (X) is above or below the mean of 
the control group (μ). Raw measures for EPM (time in open arm; % crosses into open arm), OF 
(time in center; % distance in the center), NSF (latency to feed),  and SP (sucrose consumption 
and sucrose preference) were converted to standard deviations relative to respective means of the 
control group (SstWT mice). The directionality of scores was adjusted so that decreased score 
values indicated reduced anxiety/depressive-like behaviors (termed emotionality). Finally, values 
across tests were averaged for each mouse to produce individual emotionality Z-scores. 
Locomotion Z-scores were similarly applied and obtained from EPM (total crosses) and OF 
(Total distance traveled) data.  
3.3.4 Physiological Evaluation  
The body weight and coat state of all the animals were assessed and scored (0-2 points) weekly 
by a double-blinded experimenter until the end of the UCMS treatment. The total score of the 
coat state resulted from the sum of the score of five different body parts: head, neck, dorsal and 
ventral fur, tails and paws. A score of 0 was given for a well-groomed fur and increased to 2 for 
an unkempt fur. 
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3.3.5 Estrous phase  
Female mice were assessed for estrous phase on the day of behavioral testing (EPM, OF, NSF, 
SP) to control for potential effects of hormonal fluctuations on behavior. Estrus, metestrus, 
diestrus, and proestrus were determined via vaginal cytology. 
3.3.6 Real-time quantitative polymerase chain reaction  
Brains were flash frozen on dry ice after sacrifice. Bilateral cingulate cortex (between bregma +  
1.42 to -0.5 mm; Figure 2) was obtained using a cryostat and a 1-mm-bore tissue punch.  
 
Figure 2. Coronal section of mouse brain.  
Aadapted from “The mouse brain” G. Paxinos, (2008). For sampling of mouse cingulate cortex, the tissue punch 
was placed in the circled area. Cg1: cingulate cortex, area 1. Cg2: cingulate cortex, area 2. 
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Total RNA from mouse cingulate cortex was extracted using the RNeasy Micro Kit (Qiagen) 
according to the manufacturer’s instructions. Reverse transcription reaction was performed using 
the qScript cDNA Supermix (Quanta Biosciences, Gaithersburg, MD). As previously described 
(Sibille et al., 2009b), all validated primer sets were listed in Table 2 (Tripp et al., 2012). The 
comparative threshold cycle (Ct) measurement was performed for quantification with SYBR 
green fluorescence signal (Invitrogen, Carlsbad, CA) using a Mastercycler® ep Realplex2 real-
time PCR machine (Eppendorf, Westbury, NY). PCR thermal cycling was 65°C to 59°C touch-
down followed by 40 cycles (95 ˚C for 10 sec, at 59 ˚C for 10 sec, and 72 ˚C for 10 sec).  
Samples were run in triplicate and the difference in cycle threshold (∆Ct) values for each 
GABA/BDNF-related transcript was determined by comparison to the geometric mean of three 
control genes (actin, GAPDH, cyclophilin). The relative expression level of each targeted 
transcript was determined as 2-dCt. 
Table 2. Primer pairs. 
Gene Accession Size Forward primer Reverse primer 
Neuropeptide 
Y (Npy) 
NM_023456.2 146 CAGCCCTGAGACACTGATT AGATGAGATGAGGGTGGAAA 
Cortistatin 
(Cort) 
NM_007745.3 
 
72 CCTTCTCCTCGTGCAAGTA AGGTCTCGTTGGCATCTC 
Brain-
derived 
neurotrophic 
factor (Bdnf) 
NM_001048139.1 159 CATTGAGCTCGCTGAAGTTG ACCTGGTGGAACTTCTTTGC 
Glutamic acid 
decarboxylase 
67 (GAD67) 
NM_008077.4 76 AGACCTCCGATACACTGACC TGCACACCCTAAATGCAC 
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3.3.7 Statistical analysis 
Statistical analyses were carried out using GraphPrism Version 6.0 (Graph Pad. Software Inc., 
San Diego, CA, USA). Student’s t test was used to compare means between two groups. 
Correlations between food consumption and emotionality/latency to feed were assessed by 
Pearson correlation. All data are expressed as means ± standard error of the mean. Statistical 
significance was set at p < 0.05. SstKO mice display high baseline/trait emotionality. 
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3.4 RESULTS 
3.4.1 SstKO mice display high baseline/trait emotionality 
To investigate the role of SST in mood regulation, we characterized baseline/trait 
anxiety/depressive-like behaviors in SstKO mice under baseline unstressed conditions. We 
employed emotionality z-scores to summarize the results from different behavioral tests. For the 
first analysis, results from independent tests were as follows: in the EPM, SstKO mice spent 
comparable time in and had a comparable number of entries into the open arms; in the OF, SstKO 
mice spent significantly less time (p < 0.05) and entered proportionately less often (p < 0.05) into 
the center compared to controls); in the NSF, SstKO mice had significantly increased latencies to 
eat the pellet (p < 0.01); in the SP, SstKO mice had normal sucrose consumption and preference 
(Figure 3).  
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Figure 3. Assessment of anxious/depressive-like behaviors in non-stressed SstKO mice.  
Behavioral phenotypes, including anxious/depressive-like behaviors, overall emotionality scores in the elevated plus 
maze (EPM; A), sucrose preference test (SP; B), open field (OF; C), and novelty suppressed feeding test (NSF; D) 
were examined in SstKO and wild-type mice at baseline. Overall emotionality Z scores were summarized (E). * p 
<0.05, ** p <0.01. Error bars represent the standard error of the mean (N=12-15/genotype, 6-9 mice/sex). 
3.4.2 SstKO mice display normal locomotion 
While EPM and OF emotionality measures were controlled for locomotion, we found that SstKO 
mice displayed normal total entries in the EPM and total traveled distance in the OF. Consistent 
with a prior report (Zeyda et al., 2001), non-stressed SstKO mice showed normal locomotion. We 
used a locomotion z-score to summarize results in the EPM and OF tests for locomotion (Figure 
 42 
4). As there were no differences in locomotion, baseline/trait emotionality in SstKO mice was 
unlikely to reflect deficits of locomotion. 
 
Figure 4. Assessment of locomotion in non-stressed SstKO mice.  
Locomotion, including total entries in the elevated plus maze (EPM; left) and total distance in the open field (OF; 
middle), and overall locomotion scores (right), was examined in SstKO and SstWT mice. Error bars represent the 
standard error of the mean (N=12-15/group, 6-9 mice/sex). 
3.4.3 SstKO mice display normal physiological responses to chronic stress 
Chronic stress exposure is an exogenous, risk factor associated with mood symptoms (Keller et 
al., 2007), and its interaction with endogenous, genetic risk factors is shown to increase 
susceptibility to mood dysregulation (Caspi et al., 2003). UCMS is a well-validated paradigm 
that increases anxiety/depressive-like behaviors in mice and that induces neuroendocrine and 
molecular changes associated with major depression (Surget et al., 2009). To investigate the 
effects of Sst ablation on behavioral emotionality in response to stress, we exposed the same 
cohort of mice to UCMS.  
The progressive degradation of the fur coat quality clearly indicated that both groups 
significantly responded to UCMS (Figure 5A). Moreover, UCMS-induced coat changes and 
weight (Figure 5B) did not differ across groups, together demonstrating that the elevated 
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behavioral emotionality phenotype of SstKO mice did not correlate with any overall physical 
changes.  
 
Figure 5. Assessment of changes in coat state and body weight during unpredictable chronic mild stress.  
(A) The increased fur coat degradation clearly indicated that both groups significantly responded to unpredictable 
chronic mild stress (UCMS), and no differences between SstKO and wild-type (WT) mice. (B) No differences in 
weight gain between SstKO and SstWT mice. (N=12-15/group, 6-9 mice/sex). 
3.4.4 SstKO mice display high state emotionality after chronic stress 
Behavioral testing in the last two weeks of the 8-week UCMS protocol found increased latency 
to feed in the NSF test (Figure 6D) and higher emotionality z-scores ((Figure 6E) in stressed 
SstKO mice, compared to stressed SstWT mice. Although normal variability in behavioral testing 
precluded comparison of absolute values across time in a longitudinal study design (baseline 
followed by post-UCMS behavioral testing), we did not find any genotype by stress interaction, 
instead SstKO mice maintained a similarly higher behavioral emotionality over SstWT littermates 
under baseline unstressed [1.51 ± 0.17 fold (s.e.m.) relative to control] and stressed conditions 
[1.69 ± 0.11 fold (s.e.m.) relative to control].  
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Figure 6. Assessment of anxious/depressive-like behaviors in SstKO mice after UCMS.  
Behavioral phenotypes, including anxious/depressive-like behaviors and overall emotionality scores in the elevated 
plus maze (EPM; A), sucrose preference test (SP; B), open field (OF; C), and novelty suppressed feeding test (NSF; 
D) were examined in SstKO and SstWT mice after UCMS. Overall emotionality Z scores were summarized (E). ** p 
<0.01, **** p < 0.001. Error bars represent the standard error of the mean (N=12-15/group, 6-9 mice/sex). 
3.4.5 SstKO mice display normal locomotion after chronic stress 
Following UCMS treatment, locomotion was reduced in stressed SstKO mice in the open field but 
not in the EPM or overall locomotion Z-score (Figure 7) compared to stressed SstWT mice.  
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Figure 7. Assessment of locomotion in SstKO mice after UCMS.  
Locomotion, including total entries in the elevated plus maze (EPM; left) and total distance in the open field (OF; 
middle), and overall locomotion scores (right), was examined in SstKO and SstWT mice after UCMS. * p <0.05. Error 
bars represent the standard error of the mean (N=12-15/group, 6-9 mice/sex). 
3.4.6 Validation of emotionality in SstKO mice using an independent cohort 
To replicate previous findings on behavioral emotionality, we used a second independent cohort 
of mice to examine the robustness of the SSTKO mouse phenotypes. Consistent with previous 
results, we confirmed that increased latency to feed in the NSF test and higher emotionality z-
scores in SstKO  mice compared to normal SstWT  mice (Figure 8).  
 
Figure 8. Validation of anxiety/depressive-like behaviors in unstressed SstKO mice.  
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Behavioral phenotypes, including anxious/depressive-like behaviors and overall emotionality scores in the elevated 
plus maze (EPM), sucrose preference test (SP), open field (OF), and novelty suppressed feeding test (NSF) were 
examined in SstKO and SstWT  mice at baseline. Overall emotionality Z scores were summarized at the bottom. ** p 
<0.01. Error bars represent the standard error of the mean (N=17-19/genotype, 8-11 mice/sex). 
 
Following UCMS exposure, stressed SstKO mice maintained a higher behavioral 
emotionality compared to stressed SstWT littermates (Figure 9). Thus, the behavioral phenotypes 
of SstKO mice were reproduced independently. 
 
Figure 9. Assessment of anxiety/depressive-like behaviors in SstKO mice after UCMS in a second, independent 
cohort.  
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Behavioral phenotypes, including anxious/depressive-like behaviors, overall emotionality scores in the elevated plus 
maze (EPM), sucrose preference test (SP), open field (OF), and novelty suppressed feeding test (NSF) were 
examined in SstKO and wild-type mice at baseline and after UCMS. Overall emotionality Z scores were summarized 
at the bottom. # p <0.1, *** p< 0.005. Error bars represent the standard error of the mean (N=17-19/group, 8-11 
mice/sex). 
 
3.4.7 Home-cage food consumption in SstKO mice following food deprivation and NSF test  
Notably, in the NSF paradigm, we measured appetitive drive by measuring the amount of food 
consumed in the home cage for 6 min, upon reaching the food pellets in an open-field arena. In 
the first cohort, we found a small but significant reduction in food consumption in SstKO mice 
immediately following the NSF test under baseline unstressed conditions, but not after UCMS 
exposure (Figure 10). In the second cohort, there was a trend for SstKO mice to eat less food 
under unstressed and post-UCMS conditions (Figure 10). 
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Figure 10. Assessment of food consumption after 16 hours of food deprivation and NSF test in SstKO mice.  
In the first cohort, unstressed SstKO mice ate less food when they returned to their home cage after NSF testing. 
Stressed SstKO mice had normal food consumption when they returned to their home cage. In the first cohort, a trend 
of reduced food consumption under unstressed and stressed conditions. *p <0.05,  # p <0.1. Error bars represent the 
standard error of the mean (N=12-19/group, 6-11 mice/sex). 
To explore the relationship between post-NSF food consumption and anxiety/depressive-
like behaviors (i.e. latency to feed) during the NSF, we examined the correlation between food 
consumption and latency to feed in two cohorts of SstKO mice under baseline and after CUMS 
conditions. We found no significant correlation under baseline (p = 0.77, r = -0.05) or after 
UCMS (p = 0.24, r = -0.23) conditions (Figure 11A). In addition, no significant correlation 
between home-cage food consumption and baseline/trait emotionality (p = 0.95, r = 0.01) or 
post-UCMS state emotionality (p = 0.81, r = 0.047) was found in SstKO mice (Figure 11B).  
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Figure 11. Assessment of food consumption after 16 hours of food deprivation and NSF test in SstKO mice.  
In the first cohort, unstressed SstKO mice ate less food when they returned to their home cage after NSF testing. 
Stressed SstKO mice had normal food consumption when they returned to their home cage. In the first cohort, a trend 
of reduced food consumption under unstressed and stressed conditions. *p <0.05,  # p <0.1. Error bars represent the 
standard error of the mean (N=12-19/group, 6-11 mice/sex). 
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Moreover, compared to wild-type littermates, the body weight of SstKO mice was 
consistently normal, even after 16 hours of food deprivation for NSF. Collectively, this aberrant 
feeding behavior immediately after NSF testing could be interpreted as post-NSF residual 
anxiety-like behavior that suppresses food consumption at home cage for a short period of time.   
Again, the results indicated that the elevated behavioral emotionality phenotype of SstKO mice 
did not correlate with any overall physical changes.  
3.4.8 Female SstKO mice display more robust emotionality phenotypes  
To explore potential sex differences in SstKO mouse phenotypes, we separated the above-
described data by sex groups (male and female cohorts) in the NSF analyses. We observed that 
the increased anxiety/depressive-like behaviors in the NSF were more robust in female SstKO 
mice under baseline and chronic stress conditions (Figure 12). Note that there was no statistical 
interaction between sex and treatment, indicating that the results in female SstKO were more 
robust rather than different from male SstKO.   
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Figure 12. Increased SstKO female vulnerability to high anxiety/depressive-like behaviors in the NSF test.  
Female SstKO mice showed more robust phenotypes in NSF under baseline unstressed (trait-like; A, C) and chronic 
stress (B, D) conditions. Males are in blue, females in red. Hashed bars indicate chronic stress groups. * p <0.05, 
***  p < 0.005. Error bars represent the standard error of the mean (N=6-9 mice/sex). 
 
At baseline, there was a trend for female SstKO mice to display higher emotionality that 
integrated four behavioral tests (p < 0.1; Figure 13B) compared to female SstWT mice. After 
UCMS exposure, stressed female SstKO mice showed significantly higher emotionality (p < 
0.005; Figure 13D) compared to stressed female SstWT mice. Overall, high emotionality of SstKO 
mice appeared driven by female mice, revealing an interesting parallel with the heightened 
human female vulnerability to mood disorders (Perugi et al., 1990; Kornstein et al., 2000).  
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Figure 13. Assessment of sexually dimorphic role of SST in behavioral emotionality.  
In contrast to male mice (A, C), female SstKO mice showed more robust phenotypes at baseline (B) and after chronic 
stress (D). # p <0.1, ***  p < 0.005. Error bars represent the standard error of the mean (N=6-9 mice/sex). 
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3.4.9 Molecular phenotypes and functional compensation of BDNF-GABA signaling in 
mice with low SST 
SST is a cellular marker overlapping with NPY, CORT, and the 67 kDa isoform of GABA-
synthesizing enzyme glutamic acid decarboxylase (GAD67), together contributing the majority 
of inhibitory input onto pyramidal dendrites (de Lecea et al., 1997; Viollet et al., 2008). 
Expression of these GABA markers is down-regulated in the anterior cingulate cortex and 
amygdala of depressed patients, and in mice with reduced BDNF (Tripp et al., 2011; Guilloux et 
al., 2012; Tripp et al., 2012), suggesting a vulnerable BDNF/GABA-enriched gene module in 
SST neurons associated with mood regulation. To examine whether loss of SST affected this 
particular gene module, we performed qPCR to measure Cort, Npy, Gad67, and Bdnf expression 
in the cingulate cortex of mice with low SST. Results show that SST ablation induced further 
changes, including low expression of Cort, Bdnf, and Gad67 (Table 3), when compared to SstWT 
mice. Notably, the gene profile observed in SstKO mice was similar to key gene changes observed 
in mice with altered BDNF function and in depressed patients. On the other hand, SstHZ mice 
showed elevated Cort and reduced Bdnf expression (Table 3). 
 
Table 3. Altered expression of Bdnf and GABA-related genes in SstKO and SstHZ mice, and comparison to mice 
with low BDNF, and to human subjects with MDD.  
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 (Left) Altered expression of Bdnf and GABA-related genes in SstKO and SstHZ mice. (Right) Bdnf-dependency of 
Cort and Npy expression is shown in BdnfHZ and Bdnf exon-IV knockout mice (From Tripp et al., 2012) and core 
depression-related gene profile in human subjects (From Guilloux et al., 2011; Tripp et al., 2012; # represents 
decreased BDNF-TrkB signaling in postmortem corticolimbic regions of depressed subjects). Error bars represent 
the standard error of the mean (n = 8-16/ per genotype). 
3.5 CONCLUSION AND DISCUSSION 
A conserved molecular feature in neurological disorders is consistently reduced SST; hence, we 
previously hypothesized that SST deficits play a causal role in mood dysregulation across 
diseases (Lin & Sibille, 2013). Moreover, expression of co-localized markers (i.e., GAD67, 
NPY, CORT) in depressed patients is consistently reduced, indicating a robust cell-based 
pathology in depression (Tripp et al., 2011; Guilloux et al., 2012). Our findings indicate that 
SstKO mice recapitulate behavioral (high emotionality) and molecular (down-regulated 
BDNF/GABA profile) phenotypes that are observed in depressed patients and thought to be 
involved in mood dysregulation. Hence, our results suggest that SST deficits may work as an up-
stream factor, contributing to dysfunctional inhibitory neurotransmission and mood 
dysregulation.  
The present study shows that unstressed SstKO mice exhibit anxiety/depressive-like 
behaviors in the open field and novelty-suppressed tests.  In previous pharmacological studies, 
microinjections of SST isoforms (SST-14 and SST-28) into amygdala or ventricle exert 
anxiolytic effects on anxiety-like behaviors in the elevated plus maze (Yeung et al., 2011; Yeung 
& Treit, 2012). Zeyda et al., (2001) indicated that unstressed SstKO mice displayed  non-
significant trend ( p > 0.08) toward increased anxiety-like behaviors in the light/dark-avoidance 
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test but not in the open field test ( p > 0.3) (Zeyda et al., 2001). Albrecht et al., (2013) further 
investigated SstKO mice in two days of the dark cycle (during rodent active phase) and found that 
non-stressed SstKO mice showed increased anxiety-like behaviors during the second, but not the 
first day of the active phase (Albrecht et al., 2013). Zeyda et al., (2001) maintained the SstKO 
mice on a 129/Sv-background and used the F2 generation (two generations after the founder 
line). In the present study, animals originated from breeding SstHZ mice that were backcrossed 
into the C57BL/6J inbred mouse strain for one generation during importation. We speculate that 
the discrepancies of the observed behavioral phenotypes might be due to different genetic 
backgrounds and time points of testing. 
No significant correlation between home-cage food consumption and baseline/trait 
emotionality (r = 0.01, p = 0.95) or post-UCMS state emotionality (r = 0.05, p = 0.81) was found 
in SstKO mice. In addition, SstKO mice displayed normal body weight compared to wild-type 
littermates, under all conditions. Together these control studies did not identify any consistent 
pattern of differences and thus suggest that the increased latency to feed in the NSF and the 
overall elevated behavioral emotionality of SstKO mice were not confounded by physiological or 
activity changes. 
Cortistatin (Cort) binds to all SST receptors and shares similar structural, functional, 
pharmacological properties with SST (de Lecea, 2008). In contrast to previous SstKO studies that 
did not find changes or compensatory up-regulation of Cort (Zeyda et al., 2001; Ramirez et al., 
2002; Cammalleri et al., 2006), we found that Cort mRNA levels in the cingulate cortex were 
significantly down-regulated in SstKO mice, but upregulated in SstHZ mice. One previous study 
has found that SST expression is normal in Cort knockout mice (Zeyda & Hochgeschwender, 
2008); however, little is known about SST expression in Cort null mutant animals. The 
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inconsistent molecular effects in SST and Cort expression suggest that the effects of SST on 
Cort expression are possibly regulated in a dose- and regionally specific manner. In addition, we 
speculate that compensatory upregulation in Cort may account for generally better preserved 
SST functions in SstHZ and thus prevents high behavioral emotionality. The observation of down-
regulated Bdnf expression further implicates homeostatic changes in Bdnf as an upstream 
regulator of SST expression (Tripp et al., 2012). Finally, our data also demonstrate that 
additional factors might be at play in SST-associated mood regulation since low Gad67 was 
observed in SstKO but not in SstHZ mice.  
Overall, mice with low SST provide a valuable genetic model for investigating mood 
dysregulation and antidepressant efficiency. In addition, it remains to be seen whether loss of Sst 
in specific regions and developmental stages is critical for affect dysregulation. 
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4.0  ROLE OF CORTICOSTERONE IN SOMATOSTATIN-RELATED 
EMOTIONALITY 
 
4.1 ABSTRACT 
Hyperactivity of the HPA axis is observed in some depressed patients, and elevated stress 
hormones can lead to depression, although these are not consistent observations. A known 
physiological function of SST is neuroendocrine modulation, as confirmed by SstKO mice 
displaying elevated circulating corticosterone. Thus, we were interested in whether the observed 
differences of emotionality between SstKO and SstWT mice were mediated by HPA dysregulation. 
We also characterized the behavioral emotionality in SstHZ mice, and assessed the responsiveness 
of the HPA axis in mice with low SST by measuring plasma corticosterone during the basal, 
acute restraint stress, and recovery periods. Consistent with previous observations, we found 
high basal plasma levels of corticosterone in SstKO mice. We further found that SstHZ mice 
displayed similar elevated corticosterone levels, but surprisingly normal behavioral emotionality 
under baseline unstressed and chronic stress conditions. The HPA axis responses to restraint 
stress and following 1-h recovery were normal in both SstKO and SstHZ mice. Hence, these 
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observations indicate that high basal levels of the corticosterone in mice with low SST may not 
sufficiently increase emotionality. 
4.2 INTRODUCTION 
The HPA axis is a major neuroendocrine system that regulates stress responses. Neurons within 
the medial parvocellular subdivision of the paraventricular nucleus (mpPVN) in the 
hypothalamus synthesize corticotropin-releasing hormone (CRH). The released CRH binds to 
CRHR1/CRHR2 receptors on the cell membrane of corticotrophs, which then synthesize and 
release adrenocorticotropic hormone/corticotrophin (ACTH). The HPA axis is activated by a 
brief secretion of ACTH, followed by the negative feedback of glucocorticoids on ACTH and 
CRH release (Tasker & Herman, 2011; Myers et al., 2014). Corticosterone, the major murine 
glucocorticoid (cortisol in humans, non-human primates; stress hormones) and final effector of 
the HPA axis, is synthesized by the cortex of adrenal glands in response to ACTH. 
Glucocorticoids can in turn affect the overall balance of limbic neurons to control behavioral 
stress responsiveness. Hyperactivity of the HPA axis is observed in some depressed patients 
(Gold & Chrousos, 1999; Wong et al., 2000), and elevated glucocorticoids can lead to depression 
(Starkman et al., 1981; Kathol, 1985; Murphy, 1991). Because a known physiological function 
of SST is neuroendocrine modulation, past research in SST has mostly focused on its 
neuroendocrine-related function (Patel, 1999). SST knockout mice display elevated circulating 
corticosterone (Zeyda et al., 2001; Luque et al., 2006). However, how glucocorticoids contribute 
to SST-related behavioral phenotypes remains unclear. Hence, the current study provided an 
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extended characterization of corticosterone profile in mice with low SST (heterogeneous and 
homogeneous), and explored the correlation of high corticosterone with behavioral emotionality.  
4.3 MATERIALS AND METHODS 
4.3.1 Animals  
SstKO, SstHZ, SstWT littermates were generated by crossing SstHZ mice. The SstKO mouse line was 
purchased from the Jackson Laboratory (stock no. 008117) (Zeyda et al., 2001).  Genotypes were 
identified by PCR analysis of DNA isolated from tail cuts. Cohort 4 consisted of 71 mice 
[Control group: n = 21 SstWT (11 males, 10 females), 14 SstHZ (6 males, 8 females); UCMS 
group:   n = 20 SstWT (10 males, 10 females), 16 SstHZ (7 males, 9 females)] and was used 
exclusively for behavioral assessments. Accordingly, cohort 4 was tested in EPM, OF, NSF, and 
SP at 5 months of age. Cohort 5 consisted of 40 mice [n =13 SstWT (6 males, 7 females), 14 SstHZ 
(7 males, 7 females), 13 SstKO (7 males, 6 females)] and was used to examine HPA axis function. 
The use of animals, including all treatments, was conducted in compliance with the NIH 
laboratory animal care guidelines and with protocols approved by the Institutional Animal Care 
and Use Committee of the University of Pittsburgh. All experiments were performed with 3- to 5 
month-old male and female mice littermates, between 9 am and 3 pm. All mice were group 
housed and maintained under standard conditions (12/12-hour light/dark cycle, lights on at 07:00 
h), 22 ± 1°C, with food and water ad libitum). 
 59 
4.3.2 Corticosterone Measurements  
The stress reactivity test consisted of a 30-min restraint period, corresponding to an acute, 
moderate stressor. The blood samplings were drawn at three time points: immediately before, 
during a 30-min exposure to restraint stress, as well as 60 min after ending the stress session 
(recovery period). The animals were restrained in a 50-ml Falcon tube with a ventilation hole and 
a hold in the lid for the tail. Tail blood (30 μl) from mice was collected into a Microtainer® tube 
with Lithium Heparin (BD Vacutainer Systems, Franklin Lakes, NJ) at 10:00-14:00. Bleeding 
was induced by cutting the tip of the tail, and plasma was separated by centrifugation at 1200 g, 
4 °C for 10 min, and then stored at -80°C until use. All samples were ran in duplicate and 
measured by Corticosterone ELISA Kit (EnzoLife Sciences, Farmingdale, NY) according to the 
instructions of the manufacturer. 
4.3.3 Unpredictable chronic mild stress 
Mice were subjected to six weeks of a random schedule consisting of 1-3 environmental stressors 
per day, seven days per week (Surget et al., 2009). Stressors included repeated bedding change, 
no bedding, reduced housing space, forced bath (~2 cm of water in cage), wet bedding, aversive 
smell (exposure to fox or bobcat urine), social stress (rotate mice into previously occupied cages 
or single-housing), 45° tilted cage, and mild restraint (stay in 50-ml falcon tube with air hole). 
Weekly assessment of weight and fur was performed to monitor physiological progression of the 
UCMS syndrome. The social isolation treatment began from the fifth week of UCMS until the 
day of euthanasia. 
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4.3.4 Behavior 
Anxiety/depressive-like behaviors were tested in the elevated plus maze (EPM), open field (OF), 
novelty-suppressed feeding (NSF), and sucrose preference test (SP) in the following order for 
each mice: EPM, OF, NSF, SP, separated by a minimum of 1 day. All tests were performed 
during the light phase of the circadian cycle, between 9 am and 3 pm.  
Elevated plus maze (EPM) 
 
 
Anxiety-like behaviors and locomotion were measured in a cross maze with two open and two 
closed arms (30 cm x 5 cm) as previously described (Sibille et al., 2000). Entries and time spent 
in the open arms were recorded for 10 min to assess anxiety-like behaviors. Total number of 
entries was assessed as an index of locomotion. 
 
Open field (OF) 
Anxiety-like behaviors and locomotion were measured in a 76 x 76 cm chamber divided in 16 
even-size squares and monitored for 10 min using the Any-maze video-tracking software. 
Percentage of walking distance and time spent in the four center squares were assessed to 
evaluate anxiety-like behaviors. Total walking distance in the chamber was used as an index of 
locomotion.   
 
Novelty-suppressed feeding (NSF) 
Anxiety/depressive-like behaviors were measured for 11 min in a 76 x 76 cm chamber, with a 
food pellet in the bright-lit center. The drive to overcome the aversive center was increased by 16 
hours of food deprivation before testing. The latency to start eating food pellet was measured as 
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an index of anxiety/depressive-like behaviors. Six minutes of food consumption in the home 
cage after the test was used as a measure for appetite after NSF testing and food deprivation.   
 
Sucrose preference test (SP) 
The sucrose test was performed using a two-bottle test: a bottle filled with a 2% sucrose solution 
and a bottle filled with water. Mice had free access to both water and a 2% sucrose solution 48 
hours before the test in their home cage to reduce neophobia. For the next two days, a sucrose 
preference/consumption test began in a new single-house cage for 16 h from 18:00 pm-10:00 am. 
Position of bottles was counterbalanced across the left and the right sides from test to test. 
Sucrose preference (percent) was calculated as follows: preference = [sucrose solution intake 
(ml)/total fluid intake (ml)] × 100. Sucrose consumption was calculated as: consumption = 
[sucrose solution intake (ml)/ body weight (g)]. 
 
Z-scoring 
To investigate the consistency of behavioral performance across related tests, emotionality- or  
locomotion- related data were normalized using a Z-score methodology, as previously described 
(Guilloux et al., 2011). Z-scores calculate how standard deviation (σ) and observation (X) is 
above or below the mean of the control group (μ). Raw measures for EPM (time in open arm; % 
crosses into open arm), OF (time in center; % distance in the center), NSF (latency to feed),  SP 
(sucrose consumption and sucrose preference) were converted to standard deviations relative to 
respective means of the control group (Sst WT mice). The directionality of scores was adjusted so 
that decreased score values indicated reduced anxiety/depressive-like behaviors (termed 
emotionality). Finally, values across tests were averaged for each mouse to produce individual 
 62 
emotionality Z-scores. Locomotion Z-scores were similarly applied and obtained from EPM 
(total crosses) and OF (Total distance traveled) data.  
4.3.5 Physiological Evaluation  
The body weight and coat state of all the animals were assessed and scored (0-2 points) weekly 
by a double-blinded experimenter until the end of the UCMS treatment. The total score of the 
coat state resulted from the sum of the score of five different body parts: head, neck, dorsal and 
ventral fur, tails and paws. A score of 0 was given for a well-groomed fur and increased to 2 for 
an unkempt fur. 
4.3.6 Statistical Analysis 
Statistical analyses were carried out using GraphPrism Version 6.0 (Graph Pad. Software Inc., 
San Diego, CA, USA). Student’s t test was used to compare means between two groups, and 
one-way or two-way analysis of variance followed by Tukey’s post hoc among means were used 
to determine significant differences among multiple groups. All data are expressed as means ± 
standard error of the mean. For brevity, uninformative non-significant results were omitted from 
the text.  
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4.4 RESULTS 
4.4.1 Mice with low SST display high basal corticosterone 
It was previously reported that SstKO mice showed high basal levels of plasma corticosterone 
(Zeyda et al., 2001). Our findings are consistent with this observation, and found high basal 
plasma levels of corticosterone in both SstKO and SstHZ mice (Figure 13A). In addition, stress-
induced and recovery levels of corticosterone were normal in SstKO and SstHZ mice (ANOVA p > 
0.05; Figures 13B-C). 
 
Figure 14. Altered basal levels of corticosterone in SstKO and SstHZ mice.  
(A) Altered basal levels of corticosterone (CORT) in SstKO and SstHZ mice. (B) Acute stress-induced corticosterone 
levels were normal in mice with low SST. (C) No abnormal corticosterone levels were detected in mice with low 
SST during the recovery period.* p <0.05. Error bars represent the standard error of the mean (N=13-14/genotype). 
4.4.2 SstHZ mice display normal baseline/trait and state emotionality 
To gain insight into the role of SST and corticosterone in mood regulation, we examined SstHZ 
and SstWT mice treated with UCMS or remained unstressed. Based on previous findings in MDD 
and SstKO mice, we predicted that SSTHZ mice would display high emotionality under basal 
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unstressed and chronic stress conditions. Surprisingly, when compared to SstWT mice, SstHZ mice 
exhibited normal behavioral phenotypes. In addition, Z-score analyses revealed that UCMS 
treatment increased emotionality in SstHZ and SstWT mice, but to a similar extent in SstHZ and 
SstWT mice (Figure 14; details in Appendix B).  
 
 
Figure 15. Assessment of anxiety/depressive-like behaviors in SstHZ mice under baseline unstressed and 
chronic stress conditions.  
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Overall emotionality Z scores indicated that UCMS increased emotionality in SstHZ and SstWT mice, and SstHZ mice 
exhibited normal emotionality compared to SstWT mice under baseline unstressed or chronic stress conditions. * p 
<0.05, ** p <0.01, *** p < 0.005. Error bars represent the standard error of the mean (N=14-21/group, 6-11 
mice/sex). 
4.4.3 SstHZ mice display normal locomotion 
Consistent with prior results in SstKO mice, we measured locomotion and found that SstHZ 
exhibited normal locomotion in the EPM and OF tests (Figure 15). Compared to non-stressed 
controls, UCMS-treated SstHZ and SstWT mice were significantly more hyperactive in the EPM 
and OF test, and displayed higher overall locomotion Z-scores. No genotype effects nor 
interactions were found. 
 
 
Figure 16. Assessment of locomotion in SstHZ mice.  
Locomotion, including total entries in the elevated plus maze (EPM; A), total distance in the open field (OF; B), and 
overall locomotion scores (C), was examined in SstHZ and SstWT mice under baseline unstressed or chronic stress 
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(UCMS) conditions. * p <0.05, ** p <0.01, *** p < 0.005, **** p < 0.001.  Error bars represent the standard error of 
the mean (N=14 -21/genotype/group). 
4.4.4 Home-cage food consumption in SstHZ mice following food deprivation and NSF test 
Consistent with prior NSF results from SstKO mice, SstHZ mice displayed less 6-min food 
consumption in their home cage (Figure 16A). However, SstHZ mice exhibited normal body 
weight and normal behavioral emotionality under baseline unstressed and chronic stress 
conditions. In addition, there was no significant correlation between emotionality z-scores and 
food consumption (Figure 16B; p > 0.05; r = - 0.05), together further indicating that home-cage 
food consumption immediately after NSF test is not sufficient to explain the behavioral 
emotionality. 
Figure 17. Assessment of feeding differences in SstHZ mice under baseline unstressed or chronic 
stress conditions.  
(A) After NSF testing, SstHZ mice ate less food when returned to their home cage. (B) Food consumption did not 
correlate with emotionality z-scores in SstHZ mice. * p < 0.05. Error bars represent the standard error of the mean 
(N=14-21/genotype/group, 6-9 mice/sex). 
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4.5 CONCLUSION AND DISCUSSION 
HPA axis dysfunction is frequently observed in depressed patients (Gold & Chrousos, 1999; 
Wong et al., 2000). A high incidence of depression is found in Cushing's syndrome, a hormonal 
disorder caused by high levels of cortisol. Hence, we aimed to investigate whether high 
corticosterone in SstKO mice could explain the high emotionality we observed in SstKO mice. Our 
results showed that SstKO mice had high basal levels of corticosterone in the plasma. In addition, 
we found that loss of SST did not significantly impact the stress-induced fast and negative 
feedback mechanisms of the HPA axis. Interestingly, similar to SstKO mice, SstHZ mice showed 
high basal levels of corticosterone but exhibited normal behavioral emotionality, suggesting that 
while high corticosterone may be a biomarker of SST deficits, it does not directly contribute to 
mood dysregulation. In support of this notion, a previous study found no correlations among 
basal concentrations of SST, ACTH, or cortisol and the responses of these hormones following 
the treatment of synthetic corticotropin-releasing hormone in depressed subjects (Lesch et al., 
1989). Conversely, infusion of SST in healthy adult humans, at a dose that inhibited basal GH 
secretion, was linked to an activation of HPA axis by elevating plasma levels of cortisol and 
ACTH (Ambrosio et al., 1998). Under baseline unstressed conditions, basal levels of 
corticosterone release follows a circadian rhythm, with a peak at the initiation of the awaking 
cycle (Butte et al., 1976; Allen-Rowlands et al., 1980). The steady-state level of basal 
corticosterone is involved in the organization of sleep- , body growth-, and daily-related events 
(Malisch et al., 2007; de Kloet & Sarabdjitsingh, 2008). It will be of interest to examine 
circadian patterns of corticosterone in mice with low SST. Here we did not directly address the 
impact of corticosterone on SST-associated high emotionality because the administration of 
exogenous corticosterone did not normalize corticosterone after removal of adrenal glands 
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(adrenalectomy) in my own work (not shown). In addition, side effects of adrenalectomy include 
alterations in body weight, food intake, and locomotion. Addressing these confounding factors is 
essential for future experiments. As discussed above, corticosterone release is regulated by 
circadian oscillators. It remains to be determined whether SST ablation alters characteristics of 
the pulsatile pattern of corticosterone release, possibly with frequent automated blood sampling. 
If so, rhythmic patterns of corticosterone secretion are also an important component of SST-
associated emotionality that needs to be further investigated. Taken together, the data 
demonstrate that (i) basal plasma levels of corticosterone were higher in mice with low SST, 
when compared to SstWT mice, (ii) SstKO and SstHZ mice have normal stress-induced fast response 
and negative feedback regulation of HPA axis, and (iii) SstHZ mice exhibit high corticosterone 
normal mood regulation. Thus, we conclude that corticosterone is not sufficient to induce high 
anxiety/depressive-like behaviors in SstKO mice. Its potential as a biomarker indicating SST 
deficits should be further investigated. 
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5.0  MOLECULAR ADAPTATIONS OF SST NEURONS IN THE CINGULATE 
CORTEX OF STRESSED MICE 
5.1 ABSTRACT 
SST is a secretory neuropeptide and a marker of GABAergic interneuron subpopulations that 
contribute the majority of inhibitory input onto pyramidal dendrites. In the corticolimbic regions 
of depressed patients and elder people, reduced expression of SST and other co-localized cellular 
markers are observed, suggesting a selective vulnerability of SST neurons. Using cell-type 
specific transcriptome analysis, we found that mouse SST neurons in the cingulate cortex are 
more vulnerable to UCMS compared to pyramidal neurons. Markers of SST neurons (Sst and 
Gad67 expression) were down-regulated in SST neurons of stressed mice. Protein translation 
through eukaryotic initiation factor 2 (EIF2) signaling, a pathway previously implicated in 
neurodegenerative diseases, was most affected and suppressed in SST neurons of stressed mice. 
Activating EIF2 signaling with an EIF2 kinase inhibitor mitigated mouse anxiety/depressive-like 
behaviors induced by UCMS. Thus, our findings suggest that chronic stress induces imbalance of 
protein homeostasis via compromised EIF2 pathway, leading to SST deficits and mood 
dysregulation.  
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5.2 INTRODUCTION 
The GABAergic inhibitory system includes a diverse class of neurons that regulate excitatory 
glutamatergic transmission in the brain.  SST is an inhibitory modulatory neuropeptide and a 
marker for approximately 30% of GABA interneurons that do not contain parvalbumin (PV) or 
calretinin (CR) (Gonchar et al., 2007; Kubota et al., 2011). Among the inhibitory neurons, SST-
expressing interneurons preferentially target their synapses to the dendrites of cortical pyramidal 
neurons (Hendry et al., 1984; Melchitzky & Lewis, 2008; Xu et al., 2010). As a gate keeper to 
regulate information input, SST neurons are positioned to provide spatiotemporal integration of 
postsynaptic potential in local cortical circuits (Gentet et al., 2012; DeFelipe et al., 2013; Le 
Magueresse & Monyer, 2013). SST deficits in corticolimbic regions are a common feature 
observed across several neurological diseases and during aging.  Studies have identified a 
selective neuronal vulnerability of SST-containing interneurons, as lower levels of GAD67, SST, 
NPY have been identified in the corticolimbic regions in depressed or older humans (Glorioso et 
al., 2011; Sibille et al., 2011; Tripp et al., 2011; Guilloux et al., 2012). Moreover, biological 
stressors, such as seizure and electrical foot shock, have been found to affect SST interneurons or 
Sst expression (Vezzani & Hoyer, 1999; Ponomarev et al., 2010). Exposure to chronic stress is a 
main exogenous risk factor associated with mood symptoms (Keller et al., 2007), and the 
interaction of stress with endogenous, genetic risk factors is shown to increase susceptibility to 
mood dysregulation (Caspi et al., 2003). Unpredictable chronic mild stress (UCMS) is a well-
validated behavioral paradigm that increases anxiety/depressive-like behaviors in mice and that 
induces neuroendocrine and molecular changes associated with major depression (Surget et al., 
2009).  
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Unlike the candidate-based approach in Chapter 4, here we applied the unbiased 
microarray analysis to identify molecular changes in SST neurons from cingulate cortex of 
stressed mice that were exposed to UCMS. By looking at the differentially expressed target 
genes and pathways deduced from these genes, using the Ingenuity Pathway Analysis (IPA), we 
identified here the most significantly altered pathways associated with protein homeostasis, 
oxidative stress, and mitochondrial dysfunction. Eukaryotic initiation factor 2 (EIF2) signaling is 
one of the most enriched pathways in stressed SST neurons. The interest in this pathway was 
further enhanced by the recent discoveries showing that genetic or pharmacological 
manipulations of EIF2 signaling can reverse cellular and/or behavioral deficits in several 
neurodegenerative diseases (Moreno et al., 2012; Ma et al., 2013; Kim et al., 2014). In this 
chapter, we also investigated the pathological and functional significance of EIF2 signaling 
underlying mood regulation.  
5.3 MATERIALS AND METHODS 
5.3.1 Animals  
To generate SST-GFP mice, the mouse line carrying a somatostatin promoter-driven Cre 
recombinase expression (SST-ires-cre knock-in homozygous mice; Jackson Laboratory; stock 
no. 013044) was crossed with a RosaGFP-floxed reporter mouse line carrying a loxP-flanked STOP 
cassette (Ai6 Rosa26-loxP-STOP-loxP-ZsGreen; Jackson Laboratory; stock no. 008242), as described 
previously (Taniguchi et al., 2011). Cohort 6 consisted of 30 mice (Control group: 14; 
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Unpredictable chronic mild stress group: 16) and was used exclusively for the molecular 
assessments. 
5.3.2 Unpredictable chronic mild stress 
Mice (3 months of age) were subjected to six weeks of random schedule consisting of 1-3 mild 
stressors per day, seven days per week (Surget et al., 2009). Stressors included repeated bedding 
change, no bedding, reduced housing space, forced bath (~2 cm of water in cage), wet bedding, 
aversive smell (exposure to fox or cat urine), social stress (rotate mice into previously occupied 
cages or single-housing), 45° tilted cage, and restraint stress (stay in 50-ml falcon tube with air 
hole). The social isolation began from the fifth week of UCMS until the day of euthanasia. 
5.3.3 Visualization of individual neurons in mice  
For single-cell analyses, mice were rapidly transcardially perfused with 1 ml of 1X Tris-buffered 
saline and 1 ml of 4% paraformaldehyde in phosphate buffer (pH 7.4) to lightly fix tissue while 
preserving GFP signal and RNA integrity. Cryostat sections (20 μm) were cut from coronal 
blocking containing cingulate cortex, thaw-mounted onto on polyethylene napthalate membrane 
coated slides (Leica Microsystems; #11505158; Bannockburn, IL, USA) that had been treated 
with UV at 254 nm for 30 min. Before microdissection, slides for SST neurons were dehydrated 
through 100% ethanol for 10 seconds. For pyramidal neurons, cryostat sections from mice with 
GFP-tagged SST neurons were dried briefly and stored at -80˚C. Immediately before 
microdissection, slides were immersed in an ethanol-acetic fixation solution, stained with 
thionin, dehydrated with 100% ethanol, as described previously (Lin et al., 2011). Pyramidal 
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neurons were visually identified based on their location and characteristic somal morphology 
including pyramidal shape, large size, and thick apical dendrite (Figure 17; method used in 
Appendix A). 
 
Figure 18. Scheme depicting the use of laser capture microdissection (LCM) to capture cells.  
Sections stained with thionin for pyramidal neurons or two somatostatin neurons that can be observed with GFP 
signal; before LCM and after LCM.  
5.3.4 Laser microdissection and gene expression profiling  
Laser microdissection was performed using a Leica LMD6500 system under a 40×Objective in 
the fluorescence mode (for Sst cells) or bright-field mode (for Pyramidal cells). Cutting and 
collection steps were subsequently examined in fluorescent or bright-field mode. 100 cells in the 
mouse cingulate cortex (between bregma + 1.42 to -0.5 mm; as shown in 4.3.6) from a given 
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section were collected in RNA lysis buffer (Qiagen, Valencia, CA) within a 3-hour time span, 
and stored at −80 °C until further processing. Total RNA was then extracted using the 
RNeasyPlus Micro Kit (Qiagen) according to the manufacturer’s instructions. RNA samples 
were amplified with NuGEN® Ovation Pico WTA System V2 (NuGen, San Carlos, CA). The 
fragmented labeled cDNA samples were processed and hybridized to Affymetrix® Mouse Gene 
1.1 ST Array Plates (Affymetrix).  
5.3.5 Data mining 
Gene expression information was obtained with the Affymetrix console software. Genes (dataset 
targets) showing significant differences (Student t-test p <0.005, >1.2 fold cutoff) in expression 
between stressed and unstressed SST neurons were analyzed using the IPA software (Ingenuity 
Systems, Redwood, CA).  
a. Canonical pathway analysis. The Ingenuity Knowledge Database includes 642 well-
characterized, canonical pathways that were derived from journal articles, textbooks, and the 
KEGG database, all manually curated by PhD-level scientists. Canonical pathways that differed 
most significantly were determined by Fisher’s exact test. As a result, a p-value was obtained for 
determining the probability that the association between our dataset targets and the canonical 
pathway can be explained by chance. In addition, a ratio was determined by the number of 
dataset targets that map to the pathway divided by the total number of molecules that exist in the 
canonical pathway. 
b. Upstream regulator analysis. Based on previous knowledge of expected causal effects 
between upstream regulators/drugs and their target genes stored in the Ingenuity® Knowledge 
Database, this analysis predicted which upstream regulators can explain the observed alterations 
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of our dataset targets by Fisher’s exact test. As a result, a p-value was obtained for determining 
the significance of enrichment of network-regulated genes (the dataset targets downstream of an 
upstream regulator). 
5.3.6 Real-time quantitative polymerase chain reaction 
Brains were flash frozen on dry ice after sacrifice. Bilateral cingulate cortex (between bregma +  
2.34 to + 0.5 mm) was obtained using a cryostat and a 1-mm-bore tissue punch. Total RNA from 
mouse cells were amplified with NuGEN® Ovation Pico WTA System V2 (NuGen, San Carlos, 
CA). All primer sets were listed in Table 3. The comparative threshold cycle (Ct) measurement 
was performed for quantification with SYBR green fluorescence signal (Invitrogen, Carlsbad, 
CA) using a Mastercycler® ep Realplex2 real-time PCR machine (Eppendorf, Westbury, NY). 
PCR thermal cycling was 65°C to 59°C touch-down followed by 50 cycles (95 ˚C for 10 sec, at 
59 ˚C for 10 sec, and 72 ˚C for 10 sec).  Samples were run in triplicates and the difference in 
cycle threshold (∆Ct) values for each transcript was determined by comparison to a non-biased 
control gene, neurofilament (NEFM). The relative expression level of each targeted transcript 
was determined as 2-dCt.  
Table 4. Primer pairs. 
Gene Accession Size Forward primer Reverse primer 
Somatostatin (Sst) NM_009215.1 109 CAACTCGAACCCAGCAAT GGTCTGGCTAGGACAACAA 
eukaryotic 
translation 
initiation factor 2A 
(Eif2a) 
NM_001005509.2 97 TGGGACGCCTAACCTACAAC 
 
TGACCAGGAAGGACACCAAT 
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NADH 
dehydrogenase 
(ubiquinone) 1 beta 
subcomplex 4 
(Ndufb4) 
NM_026610.1 51 
TCCTAATTTCAGGCCCACTC 
 
CCTGCCACAGCTCCTAAAAG 
Glutamic acid 
decarboxylase 67 
(GAD67) 
NM_008077.4 76 AGACCTCCGATACACTGACC TGCACACCCTAAATGCAC 
neurofilament, 
medium 
polypeptide (Nefm) 
NM_008691.2 
 
 
73 GACTTCAGCCAGTCCTCGTC 
 
TCTCGTTAGAGCGGGACAGT 
5.3.7 RNAscope Assay for in situ RNA Detection 
Probe sequences of mouse somatostatin conjugated to Alexa Fluor 488, and eIF2A conjugated to 
546 were custom-made and proprietary (Advanced Cell Diagnostics, Hayward, CA). Fresh-
frozen cryostat sections (10 µm) were placed on slides and fixed in cold 4% paraformaldehyde 
for 1 hour, followed by dehydration in an ethanol series. Tissue sections were then dried at room 
temperature for 30 min, followed by protease digestion at room temperature for 10 min. Using 
RNAscope Fluorescent Multiplex Reagent Kit (Advanced Cell Diagnostics; # 32085), tissue 
sections were then rinsed in deionized water, and immediately treated with target probes, 
preamplifier, amplifier, and label probe in a HybEZ hybridization oven (Advanced Cell 
Diagnostics, Hayward, CA) according to the instructions of the manufacturer. 
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5.3.8 Microscopic Imaging 
Images were acquired using an Olympus IX71 fluorescent microscope (Olympus, Tokyo, Japan) 
and a Fast 1394 CCD Camera (QImaging, BC, Canada). Overlapping signals from different 
fluorophores were separated and visualized under a 20x objective lens with MetaMorph 
Advanced software (Molecular Devices, CA, USA). The ratio of overlapping fluorescent signal 
areas from EIF2A and SST mRNA transcripts was determined in the cingulate cortex (between 
bregma + 1.42 to -0.5 mm; as shown in 4.3.6), based on 5 microscopic images from 3 tissue 
sections of each animal (Control group: 14; Unpredictable chronic mild stress group: 14). 
5.3.9 Drug Administration  
The selective EIF2A phosphatase inhibitor complexes, Salubrinal (Millipore, Billerica, MA, 
USA) and the EIF2AK3/PERK inhibitor, GSK2606414 (Millipore, Billerica, MA, USA) were 
dissolved in 100% dimethyl sulfoxide (DMSO) and later diluted in saline (0.9% NaCl). Based on 
previous studies (Moreno et al., 2012; Ma et al., 2013; Moreno et al., 2013; Kim et al., 2014), vehicle 
(10% DMSO/saline), Salubrinal (1.5 mg/kg), and GSK2606414 (30 mg/kg) were administered 
by oral gavage once daily for 7 days to mice treated with 3 weeks of UCMS before behavioral 
testing. Concentrations were adjusted to administer 10 ml/kg. After 7 days of drug treatments, 
anxiety/depressive-like behaviors and locomotion were tested in the elevated plus maze (EPM), 
open field (OF), and novelty suppressed feeding (NSF) with the following order: EPM, NSF, OF, 
separated by one day of booster administration. All tests were performed during the light phase 
of the circadian cycle, between 9 am and 3 pm.  
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Elevated plus maze (EPM) 
 
 
Anxiety-like behaviors and locomotion were measured in a cross maze with two open and two 
closed arms (30 cm x 5 cm) as previously described (Sibille et al., 2000). Entries and time spent 
in the open arms were recorded for 10 min to assess anxiety-like behaviors. Total number of 
entries was assessed as an index of locomotion. 
 
Open field (OF) 
Anxiety-like behaviors and locomotion were measured in a 76 x 76 cm chamber divided in 16 
even-size squares and monitored for 10 min using the Any-maze video-tracking software. 
Percentage of walking distance and time spent in the four center squares were assessed to 
evaluate anxiety-like behaviors. Total walking distance in the chamber was used as an index of 
locomotion.   
 
Novelty suppressed feeding (NSF) 
Anxiety/depressive-like behaviors were measured for 11 min in a 76 x 76 cm chamber, with a 
food pellet in the bright-lit center. The drive to overcome the aversive center was increased by 16 
hours of food deprivation before testing. The latency to start eating food pellet was measured as 
an index of anxiety/depressive-like behaviors. Six minutes of food consumption in the home 
cage after the test was used as a measure for appetite after NSF testing and food deprivation.   
 
Z-scoring 
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To investigate the consistency of behavioral performance across related tests, emotionality- or  
locomotion- related data were normalized using a Z-score methodology, as previously described 
(Guilloux et al., 2011). Z-scores calculate how standard deviation (σ) and observation (X) is 
above or below the mean of the control group (μ). Raw measures for EPM (time in open arm; % 
crosses into open arm), OF (time in center; % distance in the center), and NSF (latency to feed) 
were converted to standard deviations relative to respective means of the control group (SstWT 
mice). The directionality of scores was adjusted so that decreased score values indicated reduced 
anxiety/depressive-like behaviors (termed emotionality). Finally, values across tests were 
averaged for each mouse to produce individual emotionality Z-scores. Locomotion Z-scores 
were similarly applied and obtained from EPM (total crosses) and OF (Total distance traveled) 
data.  
5.3.10 Statistical Analysis 
Statistical analyses were carried out using GraphPrism Version 6.0 (Graph Pad. Software Inc., 
San Diego, CA, USA). Student’s t test was used to compare means between two groups, and 
one-way or two-way analysis of variance followed by Tukey’s post hoc among means were used 
to determine significant differences among multiple groups. All data are expressed as means ± 
standard error of the mean. For brevity, uninformative non-significant results were omitted.  
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5.4 RESULTS 
5.4.1 Unpredictable chronic mild stress affects the transcriptome of SST neurons but not 
pyramidal cells 
To investigate whether the above-described changes in BDNF/GABA/SST gene module 
correspond to broader molecular changes in SST neurons, we applied UCMS to mice expressing 
green fluorescent protein (GFP) in SST neurons, captured GFP-positive SST neurons and 
thionin-stained pyramidal neurons from cingulate cortex using laser capture microdissection 
(LCM), and analyzed RNA profiles of neurons from non-stressed and UCMS-exposed mice, 
using Affymetrix Gene 1.1 ST microarrays. First, we constructed probability density histograms 
for the alterations of all gene probesets in SST neurons (Figures 18A-B, red bins) and pyramidal 
neurons (Figures 18A-B, black bins), including effect sizes and statistical significance values. 
Patterns of expression alterations were strikingly different between SST neurons and pyramidal 
neurons (Kolmogorov-Smirnov test, p < 0.001). We found that UCMS affected a large portion of 
the entire transcriptome of SST neurons, as the frequency distributions of effect size beyond ± 
0.3 (changes > 20%; Figure 18A) and significance beyond 1.3 (p < 0.05; Figure 18B) were 
relatively large in SST neurons from mice exposed to UCMS. In addition, the robust shift to the 
left in effect size combined with the peak in low p-values distribution in SST neurons indicated 
profound transcriptome alterations in SST neurons, and mostly characterized by down-regulated 
expression. In contrast, we observed mostly small and non-significant changes of gene 
expression in stressed pyramidal neurons. 
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Figure 19. Stress effects on the whole transcriptome profiles in SST-containing interneurons and pyramidal 
neurons. 
Distributions of stress effects for (A) effect size (Average log2 ratio; Alr; changes > 20%; horizontal dashed lines) 
and (B) significance (p-value; p < 0.05; horizontal dashed lines) of all expressed probesets in SST interneurons (red 
lines) and pyramidal neurons (PYR; black lines) were presented as density plots. These probability distributions 
between SST neurons and pyramidal neurons were significantly different (Kolmogorov-Smirnov test, p < 0.001). 
5.4.2 Unpredictable chronic mild stress down-regulated cellular markers of SST neurons  
Sst and Gad67 were among the genes affected by UCMS, which were further confirmed by 
independent qPCR assays (Figures 19A-D). Four altered genes were chosen and confirmed by 
qPCR based on their roles in affected pathways of interest (Figures 19E). 
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Figure 20. Validation of microarray data.  
(A) Down-regulation of SST probes in SST cells exposed to UCMS. (B) Down-regulation of GAD67 probes in SST 
cells exposed to UCMS. (C-D) qPCR confirmed significant down-regulation of these genes. (E) Blank bars 
represent the percentage of fold change (UCMS-exposed SST neurons compared to non-stressed SST neurons) by 
microarray experiment; black bars represent the percentage of fold change using qPCR. A ratio of less than 0 
indicates down-regulation. The X axis showed a selected panel of genes. * p < 0.05, ** p < 0.01, . *** p < 0.005 
Error bars represent the standard error of the mean (Microarray n=14-16/group; qPCR n=12/group).   
 83 
5.4.3 Stress links SST neuronal deficits to EIF2 signaling  
To assess the biological implications of the transcriptome results, we applied IPA Canonical 
pathway analysis on differentially-expressed genes under moderate stringency (changes ≥ 20%; 
p < 0.005). Results indicated a striking enrichment of affected genes in protein and functions. 
The EIF2 pathway was the most significantly affected (p = 7.38E-21) with multiple down-
regulated genes in Sst neurons of UCMS-treated mice (Table 5).  
 
Table 5.  Top ranked canonical pathways affected in SST neurons of cingulate cortex from mice exposed to 
chronic stress.  
Genes were tested for differential expression between UCMS and control groups. Statistical significance for 
differential expression was reached at fold-change > 20% and p < 0.005. The resulting signature was submitted to 
IPA to test for over-representation of canonical pathways.  p-value was calculated by right-tailed Fisher's exact 
tests (Fisher 1922).  The ratio was calculated by the number of differentially expressed genes, divided by total 
number of genes that make up in a given pathway. 
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Up Down
EIF2 Signaling 7.38E-21 4.03E-01 PIK3CG, INS RPL11,RPL22,MAPK1,PIK3R1,PDPK1,KRAS,EIF3C/EIF3CL,RPS23,
EIF2A,RPS7,RPS3A,EIF4G2,RPL7A,EIF3D,MAPK3,RPL19,RPL8,
GSK3B,PPP1CA,RPL36A/RPL36A-HNRNPH2,RPL3,RPL27,
RPL37,RPL23A,EIF3E,RPLP0,RPL10A,RPL15,FAU,RPS4X,RPL39,
RPS15,RPS25,RPSA,EIF3K,RPL24,PPP1CC,RPS18,RPL22L1,
PPP1CB,RPS8,RPS13,RPS21,RPL35A,EIF4E,RPL7,RPL6,RPL35,
RPL18A,PIK3C3,RPS9,EIF3A,AKT3,RPS5,RPL31,RPL18,
MAP2K1,RPL29,RPL13,RPS24,RPL4,EIF3H,RPS2,RPL17,AGO2,
RPL21,RPL23,RPL9,RPS12,EIF2S2,RPS16,RPS26,RPL28,UBA52,
AGO3,EIF4A1,EIF3I,RPL38,RPS14
Oxidative Phosphorylation 8.57E-14 4.08E-01 COX6B2 NDUFA9,ATP5D,UQCR11,COX8A,NDUFB5,ATP5L,MT-CO2,
NDUFB10,NDUFA5,ATP5G1,NDUFS6,NDUFA10,ATP5F1,
ATP5G3,NDUFB3,Cycs,ATP5A1,SDHC,NDUFS5,ATP5B,
NDUFA6,NDUFB7,UQCRC2,COX5B,NDUFA4,COX7B,SDHB,
UQCRH,COX6A1,NDUFA2,Atp5e,NDUFAB1,ATP5J2,NDUFS2,
COX4I1,SDHA,NDUFV1,COX7A2,COX6B1,NDUFB4,ATP5O,
NDUFV3,NDUFS3,NDUFA11,CYC1,COX5A,NDUFA3,UQCRQ
Mitochondrial Dysfunction 2.24E-12 2.88E-01 COX6B2, LRRK2, MAP2K4,NDUFA9,ATP5D,UQCR11,COX8A,NDUFB5,ATP5L,
CPT1B MT-CO2,NDUFB10,PDHA1,NDUFA5,GPD2,ATP5G1,NDUFS6,
NDUFA10,GPX4,ATP5F1,ATP5G3,NDUFB3,ATP5A1,SDHC,GSR,
PRDX3,NDUFS5,ATP5B,NDUFA6,UQCRC2,NDUFB7,MAPK10,
VDAC1,SNCA,COX5B,NDUFA4,COX7B,SDHB,UQCRH,COX6A1,
NDUFA2,Atp5e,NDUFAB1,ATP5J2,NDUFS2,OGDH,COX4I1,
SDHA,NDUFV1,NDUFB4,COX6B1,COX7A2,ATP5O,NDUFV3,
MAPK8,NDUFS3,APP,NDUFA11,CYC1,COX5A,NDUFA3,UQCRQ
Remodeling of Epithelial 2.62E-09 4.43E-01 CDH1 NME1,RALA,RAB5B,TUBB,CLIP1,ARF6,CTNNA2,EXOC2,ARPC3,
Adherens Junctions TUBA1C,CTNNB1,ACTN1,TUBB3,TUBB4B,ACTB,TUBB2A,
TUBA4A,RAB7A,DNM3,ACTG1,TUBA1B,DNM1,TUBA1A,
ARPC1A,ARPC2,MAPRE2,ACTN4,DNM1L,ARPC4,MAPRE3
GABA Receptor Signaling 1.00E-08 4.29E-01 AP2B1,AP2A1,AP2M1,ABAT,GABRA4,UBQLN1,GABBR1,Ubb,
AP1B1,GABRB2,DNM1,GABBR2,NSF,SLC6A11,GAD2,GABRB3,
GAD1,GABRB1,SLC6A1,GABARAP,UBC,GABRA1,GABRA2,
GABRA3
Huntington's Disease Signaling 3.43E-08 2.62E-01 PIK3CG, GNG12 MAP2K4,MAPK1,PIK3R1,NAPG,PDPK1,Ubb,CDK5R1,GNB1,NSF,
CTSD,MAPK3,DLG4,PLCB1,RASA1,GRM1,IFT57,HSPA9,CLTC,
CREBBP,DNM3,GNG3,STX1A,RPH3A,ATF2,TAF9B,HDAC5,HSPA8,
DYNC1I2,DNAJC5,ATP5B,HTT,POLR2I,SNCA,SDHB,PACSIN1,
POLR2B,VTI1B,GNG7,EP300,POLR2A,PIK3C3,IGF1R,AKT3,
PRKCE,NCOR1,NAPB,SDHA,GRIN2B,GLS,MAPK8,GNAQ,Hdac9,
SNAP25,ZDHHC17,GRM5,POLR2L,DNM1,PRKCI,DCTN1,STX16,
GNG5,UBC,DNM1L,PRKCB
Protein Kinase A Signaling 6.84E-08 2.40E-01 PTPN4, GYS2, PDE6B, MYH10,MYL6,PTPN5,GNB1,CAMK2A,PLCB1,DUSP7,NFKBIB,
TNNI2,PDE12,TCF7L1, GNG12,KDELR1,PDE2A,YWHAG,PTCH1,CREBBP,YWHAZ,
TGFB2, PDE6G, TNNI3, PLCL2,PTP4A1,ATF2,ACP1,ANAPC5,PTPRA,CAMK2G,RAP1B,
TCF3, MYL10, LEF1, TCF4,Calm1,PTK2B,AKAP7,GNG7,EP300,AKAP11,PTPN4,
H2BFM, NTN1, PTPRJ,PRKCE,CTNNB1,PTPRT,PPP3CA,PTPRK,GNAQ,ADD3,
PPP1R3D, GNG12 ADD1,GNG5,PRKCB,PRKACB,MAPK1,YWHAH,PTEN,ROCK2,
Camk2b,PPP1R7,MAPK3,PPP3R1,GSK3B,PPP1CA,YWHAE,
PDE10A,YWHAB,GNG3,PTPRM,ANAPC4,H3F3A/H3F3B,
MYL12B,RHOA,PTPRS,PPP1R12A,SIRPA,PPP1CC,MYL6B,
PPP1CB,PDE1A,BRAF,PPP1R10,,PTPRN,MAP2K1,ADCY2,RYR2,
CHP1,GNAI1,PDE4D,Ptprd,PRKCI,AKAP9,PRKAR1A
Regulation of eIF4 and 1.21E-07 2.72E-01 PIK3CG MAPK1,PIK3R1,RPS18,RPS13,RPS8,PDPK1,KRAS,RPS21,PAIP2,
p70S6K Signaling RPS23,EIF3C/EIF3CL,EIF4E,EIF2A,RPS7,RPS3A,EIF4G2,EIF3D,
MAPK3,PIK3C3,RPS9,EIF3A,AKT3,RPS5,MAP2K1,RPS24,EIF3H,
RPS2,AGO2,EIF3E,RPS12,EIF2S2,PPP2CB,FAU,RPS4X,PPP2R1A,
MAPK14,RPS16,RPS26,AGO3,EIF4A1,EIF3I,RPS15,RPS25,
PPP2R5E,RPS14,RPSA,EIF3K
Ingenuity Canonical Pathways Ratio
P-Value                              
(Fisher Exact test)
Regulated Molecules (lFCl>1.2, P<0.005)
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Based on the array data, Sst expression was highly correlated with Eif2a expression 
(Figure 20A), suggesting that EIF2A may be associated with SST deficits. Downregulation of 
Eif2a expression in stress-exposed mouse Sst neurons were validated by qPCR (Figured 20B) 
and high-resolution RNAScope in situ hybridization (Figures 20C-D).  
 
Figure 21. Validation of microarray data of Eif2a.  
(A) Expression of Eif2a was highly correlated with SST expression in mouse SST neurons. (B) qPCR confirms 
significant down-regulation of Eif2a transcripts in UCMS-exposed mouse SST neurons.(C) Representative image of 
triple-labeling, high-resolution RNAscope in situ hybridization. (D) RNAscope in situ hybridization validated the 
downregulation of Eif2a in the cortical SST cells. * p <0.05, ** p <0.01. Error bars represent the standard error of 
the mean (n =12-15/group).   
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5.4.4 Upstream regulators of molecular signatures in stressed SST neurons 
To identify putative causal factors for robust changes in differentially-expressed genes (changes 
≥ 20%; p < 0.005), we applied the upstream regulators analysis in IPA that predicts upstream 
regulators based on the literature and compiled in the Ingenuity® Knowledge Base (Kramer et 
al., 2014). Surprisingly, we found that the top ranked regulators have been previously associated 
with neurodegenerative diseases (e.g., MAPT, APP, PSEN1, HTT ) (Table 6).  
 
Table 6.  Predicted Top 10 upstream regulators of transcripts affected in stressed SST neurons 
Upstream regulator p -value              
Microtubule-associated protein tau (MAPT)  1.13E-41 
Amyloid beta (A4) precursor protein(APP) 2.49E-37 
Presenilin 1(PSEN1) 1.56E-30 
Huntingtin (HTT) 6.38E-25 
N-myc proto-oncogene protein (MYCN) 2.95E-20 
CD 437 (apoptosis inducer) 2.98E-20 
Histone deacetylase 4  (HDAC4) 6.11E-20 
5-fluorouracil (antitumor agent) 4.57E-17 
sirolimus (Rapamycin; antitumor agent) 3.99E-16 
Fragile X mental retardation 1 (FMR1) 9.41E-16 
 
Note: A Fisher’s Exact Test p-value is calculated to assess the significance of enrichment of the gene expression 
data (change > 20% and p < 0.005) for the genes downstream of an upstream regulator.   
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5.4.5 EIF2 kinase inhibition blocks the development of stress-induced anxiety/depressive-
like behaviors 
If the process of EIF2 signaling is central to all neurological disorders, then it would be expected that an 
intervention that modulates this process would also affect shared symptoms, such as mood dysregulation. 
Compounds that inhibit EIF2A kinase or phosphatase have been developed and validated for use 
in mice, including for brain-related neurodegenerative models (Moreno et al., 2013; Kim et al., 
2014). Given previous findings, we predicted that stress-induced anxiety/depressive-like behaviors  
would be affected by salubrinal (an inducer of EIF2A phosphorylation via inhibiting EIF2A 
phosphatase; i.e. pathway blocked; mimic disease effects) (Boyce et al., 2005) or GSK2606414 
(an inhibitor of  EIF2A phosphorylation via inhibiting EIF2 kinase PERK; i.e. pathway 
activated; mimic therapeutic effects) (Axten et al., 2012). Results showed that, as predicted, 
anxiety/depressive-like behaviors in the NSF (Figure 21A) and overall emotionality (Figure 
21B) increased after UCMS treatment. Mice treated with GSK2606414 showed a significant 
reduction of UCMS-induced anxiety/depressive-like behaviors in the NSF (Figure 21A) and 
emotionality z-scores (Figure 21B) that were undistinguishable from control non-stressed mice. 
However, salubrinal did not significantly exacerbate UCMS-induced anxiety/depressive-like 
behaviors, suggesting either no effect of salubrinal at a dose of 1.5 mg/kg or a “ceiling effect” of 
stress on behavioral emotionality. Locomotion (Figure 21C), feeding behavior in the NSF 
(Figure 21D), anxiety-like and locomotor behaviors in EPM (Figures 21E, F, I), and OF 
(Figures 21G, H, J) were not affected by drug treatments. Together, the results suggest that 
activation of the EIF2 pathway through GSK2606414 may relieve stress-related mood 
disturbances.  
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Figure 22. Assessment of anxiety/depressive-like behaviors, locomotor activity, and feeding behavior in mice 
treated with GSK2606414 or Salubrinal. 
Assessment of anxiety/depressive-like behaviors, locomotor activity, and feeding behavior in mice treated with 
GSK2606414 or Salubrinal. Behavioral phenotypes, including scores in the novelty suppressed feeding test (NSF; 
A, B), elevated plus maze (EPM; C, D), open field (OF; E, F), locomotion in EPM (G) and OF (H), overall 
emotionality (I) and locomotion (J), were examined in mice treated with GSK2606414 or Salubrinal. * p <0.05, ** p 
<0.01, *** p < 0.005, **** p < 0.001. Error bars represent the standard error of the mean. (n = 8-12/group). 
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5.5 CONCLUSION AND DISCUSSION 
Here we used SST-GFP mice to study the effects of chronic stress on the transcriptome profiling 
of excitatory pyramidal neurons and GABAergic SST interneurons. After exposure to UCMS, 
we found a selective vulnerability of transcriptome patterns in mouse SST neurons from the 
cingulate cortex, compared to nearby pyramidal neurons (Figure 18). The mRNA expression 
levels of Sst and Gad67 were significantly decreased in stressed SST neurons. Furthermore, we 
found a significant effect of chronic stress on the pathways involved in protein translation 
initiation. Among the deregulated transcript, we observed a striking down-regulated expression 
of genes in the EIF2/EIF4/mTOR pathways and mitochondrial genes (Table 5), suggesting 
comprised protein translation and mitochondrial function in stressed SST neurons. Reductions in 
protein translation signaling may act early at ER to protect against oxidative stress and 
mitochondrial dysfunction. Interestingly, there was a positive correlation between Eif2a and SST 
expression. Furthermore, activation of EIF2 signaling with an EIF2 kinase inhibitor mitigated 
mouse anxiety/depressive-like behaviors induced by UCMS. Thus, these findings suggest that 
chronic stress suppresses protein translation via EIF2-related pathways and reduce SST-related 
genes, which may lead to mood dysregulation. 
Defects in translational control at any level (signaling pathways, general or specific 
translation factors) can contribute to disease development. Evidence in human postmortem 
studies indicated that UPR markers in the brain are temporally and spatially linked to the 
accumulation and occurrence of misfolded pathological proteins (Roussel et al., 2013; Hetz & 
Mollereau, 2014). Based on the IPA upstream regulators analysis of affected transcripts in 
stressed SST neurons (Table 5), we found that the top ranked regulators have been previously 
associated with neurodegenerative diseases (e.g., MAPT, APP, PSEN1, HTT) (Table 6). These 
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disease-linked proteins are prone to aggregation and contribute to neuronal dysfunction and 
death in neurodegeneration, includin Aβ, tau, presenilins, and huntingtin. In addition to 
supporting a link between stress and neurodegenerative processes, these findings are consistent 
with the notion that SST deficits are frequently observed in neurodegenerative diseases. 
Moreover, these results are in line with a  previous study demonstrating that  SST ablation alters 
the metabolism of amyloid β peptide (Aβ; primary pathogenic protein of Alzheimer’s disease) 
and specifically increases Aβ42 that has high amyloidogenicity and neurotoxicity (Saito et al., 
2005).  
Translation control is a key regulatory principle in regulating cell physiology and 
responses. EIF2 plays a crucial role in binding the initiator methionly-tRNA Met to the 40S 
ribosomal subunit to form a 43S preinitiation complex. The endoplasmic reticulum (ER) 
responds to environmental stress through activation of an evolutionarily conserved, protective 
mechanism termed the unfolded protein response (UPR). UPR activation directly phosphorylates 
and inhibits eukaryotic translation initiation factor 2α (EIF2A), which confers a general 
inhibition of protein translation and is thought to protect cells against the ER stress-induced 
apoptosis cascade (Harding et al., 2000). Decreased EIF2 pathway activation has been reported 
in aging process, Alzheimer’s (AD), Parkinson's disease (PD), animal models of AD, prion 
disease, and amyotrophic lateral sclerosis (Kimball et al., 1992; Nagata et al., 2007; Ma et al., 
2013; Kim et al., 2014). Subjects with AD and a murine AD model showed high eIF2A 
phosphorylation (eIF2A-P) levels, and the majority of neurons with eIF2A-P were co-localized 
with strong immunoreactivity for phosphorylated tau (Chang et al., 2002; Hoozemans et al., 
2009). Hence, there is considerable interest in understanding the functional role of EIF2 
signaling in neurological disorders.  
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A specific EIF2A kinase inhibitor (GSK2606414) has been shown to alleviate the 
development of prion infection in mice and protected neurons from prion-related 
neurodegeneration (Moreno et al., 2013). GSK2606414 is a highly selective inhibitor of Protein 
kinase R (PKR)-like ER kinase (PERK) in the UPR pathway (Axten et al., 2012). Once 
activated, PERK phosphorylates EIF2A at serine 51 to inhibit translation initiation and reduce 
overall protein synthesis. Its half-life measured in rat is approximately 2.5 hours (Axten et al., 
2013). Compared to the other optimized PERK inhibitor (GSK2656157) selected for preclinical 
development, GSK2606414 is more lipophilic and brain-penetrant and appears to be the best 
available compound for oral administration (Axten et al., 2013). However, GSK2606414 broadly 
inhibited cytochrome P450s in human liver, potentially leading to further damage to the liver 
(Axten et al., 2012). Interestingly, an inducer of EIF2A phosphorylation (salubrinal) can reduce 
the accumulation of α-synuclein in PD-model mice and delay progressive manifestations of 
weakening and paralysis in ALS-model (Saxena et al., 2009; Colla et al., 2012). However, 
salubrinal can also exacerbate neurotoxicity and reduce survival rates in prion-diseased mice, 
and enhance ER stress-mediated stress granules in ALS-model mice (Walker et al., 2013).  
These findings reflect a complex scenario of sustaining cellular proteostasis and a promising 
therapeutic target on neurodegeneration depending on the disease context and processes. As the 
last experiment in this dissertation, we directly probed whether EIF2 signaling has a functional 
role in stress-associated behavioral emotionality by treating UCMS-exposed mice with 
GSK2606414 or salubrinal. 
The maintenance of a healthy cellular proteome is essential to suppress 
neurodegeneration. We speculated that the suppressed EIF2 signaling in stressed SST neurons 
may be an early adaptive mechanism to reduce the burden of destabilized proteins associated 
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with stress, but at the cost of reduced ability to alter translational activity under chronic stress 
conditions. Hence, chronically suppressed proteostasis may increase SST deficits and make SST-
releasing neurons more vulnerable to stressors and diseases. Accordingly, one plausible 
explanation for normalized emotionality in stressed mice after  activation of EIF2 pathway via 
GSK2606414 treatment (Figure 21) would be that boosting protein translation allows stressed 
Sst neurons to exert a routine protective response, which then up-regulates stress-responsive 
genes (e.g., SST-GABA signaling) necessary for neuroplasticity and mood regulation. Salubrinal 
did not significantly exacerbate UCMS-induced anxiety/depressive-like behaviors, suggesting 
either no effect of salubrinal at a 1.5 mg/kg dose or a ceiling effect of stress on behavioral 
emotionality. 
The interactions between translational regulation and neurodegeneration in mood 
regulation have only been examined in a limited context (Calkhoven et al., 2002; Moylan et al., 
2013). Different EIF2 signaling branches of UPR might control specific cellular events 
dependent the context of neurological disorders. Future studies aimed at cell-specific alterations 
of EIF2 signaling will provide a more comprehensive coverage of complex neural circuits and 
behaviors.  Moreover, it is important, as a future study, to validate EIF2A’s role in SST neuron 
function or loss in vivo. For this, four approaches could be fruitful: (1) performing a longitudinal 
immunohistochemistry study to look at EIF2A expression in SST neurons under baseline 
unstressed condition, after acute stress, after chronic stress, during recovery from chronic stress, 
and at end-stage (i.e. after second hit of chronic stress exposure); (2) performing a similar 
immunohistochemistry study in postmortem brains of depressed subjects; (3) generating 
transgenic mice carrying SST neuron-specific null mutation of EIF2A gene by using the Cre-lox 
system and/or viral vectors. These double-engineered mice could then be used to assess the 
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impact of the EIF2A deletion within SST neurons on the onset of disease manifestations or 
during disease processes caused by UCMS; (4) investigating layer-specific alterations of cortical 
SST neurons; (5) EIF2A was only one of the top genes inferred by the IPA based on the previous 
studies; in order to understand the complete translational machinery that make SST neuronal 
dysfunction or loss, the pathological significance of the other related genes needs to be 
investigated as well.  
The most recognized function of microarray analysis is high-throughput genomic 
profiling; however, this method has several disadvantages in comparison to RNA-Seq assays and 
ribosome profiling. As discussed in recent reviews (Wang et al., 2009; Metzker, 2010; Ingolia, 
2014), microarrays have high background signals, limited dynamic range of detection, high cost 
of amplification step, and limited transcript detection that relies on prior knowledge of genome 
sequence. Additional deep sequencing to directly determine the cDNA sequence or the amount 
of proteins in stressed SST neurons is needed to provide further insights into the molecular 
mechanisms of selective vulnerability of SST neurons. 
Beyond mood disorders, a variety of mental health conditions, including Alzheimer’s 
disease, Parkinson’s disease and Huntington’s diseases, are linked to changes in SST expression 
and ER stress. Thus, our finding of suppressed EIF2 signaling in stressed SST neurons may be a 
general mechanism underlying neurological disorders, or at least often occurred in neurons under 
physiological and cellular stress. 
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6.0  GENERAL DISCUSSION 
Previous human postmortem studies raised the possibility that SST and SST-containing 
interneurons in the local cortical circuits of individuals with depression and other neurological 
disorders are altered, and thus could represent a shared common pathological feature. Therefore, 
in order to better understand the pathophysiology of SST interneurons and how SST deficits 
contribute to mood disturbances, this thesis explored behavioral alterations by SST ablation, as 
well as explored possible upstream mechanisms of selective SST neuronal vulnerability to 
chronic stress. We identified a causal role of SST in HPA hyperactivity, down-regulated BDNF-
GABA signaling, and anxiety/depressive-like behaviors in mice. However, HPA hyperactivity is 
not sufficient to explain anxiety/depressive-like behaviors associated with SST deficits. We also 
identified a selective vulnerability of SST neurons to chronic stress. Among deregulated 
pathways, translational machinery was suppressed in SST neurons of stressed mice. Activation 
of EIF2 signaling with an EIF2 kinase inhibitor mitigated anxiety/depressive-like behaviors 
induced by UCMS. Thus, mood symptoms in neurological disorders might occur when chronic 
environmental/psycho-social stressors affect the translational machinery in the cortical SST 
neurons and then compromise SST-related inhibitory neurotransmission. Our GSK2606414 
finding further suggests that EIF2 signaling may also have anxiolytic/antidepressant effects. 
Although still preliminary, the use of proteostasis therapeutics could be a unique opportunity to 
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gain further insight on the physiology of selective neuronal vulnerability and its involvement in 
mood dysregulation. 
Depression and anxiety have a high co-morbidity and co-occurrence rate (Gorman, 1996; 
Pollack, 2005), behavioral assessment from a battery of tests provides a dimensional view of 
neurobiology underlying mood regulation. Accordingly, we applied emotionality z-score to 
integrate behavioral results in the four commonly used tests, including elevated plus maze, open 
field, novelty- suppressed feeding (NSF), and sucrose preference test.  Interestingly, we 
consistently observed robust phenotypes in the NSF across different experiments in this 
dissertation.  Compared to other behavioral tests, NSF has a distinct sensitivity to detect chronic 
efficacy of antidepressants but not acute or sub-chronic treatments in rodents, which agrees with 
the clinical observations in human (Dulawa & Hen, 2005). The origins of the robust phenotypes 
in the NSF and differences in behavioral responses across tests are not known, but it could reflect 
that NSF test is sensitive to chronic SST deficits induced by genetic manipulation or UCMS.  
Every cell in the central nervous system receives cellular stress, but some types of cells 
show selective dysfunction or die during early disease or aging processes. Determinants of 
neuronal vulnerability might include cell content and location in the neural circuitry, metabolism 
of disease-specific proteins, and other stress-related mechanisms. In the following sections, I 
propose a working model of mood dysregulation that is based on results from this dissertation 
and findings from previous literature. I will also discuss some limitations of the studies in the 
thesis and propose future directions. 
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6.1 PROPOSED DISEASE MODEL IN MOOD DYSREGULATION 
The goal here is to integrate our and others results that can explain how SST is related to the 
etiology of mood disorders. Specifically, this dissertation tried to answer the following questions: 
does low SST play a causal factor in mood disturbances? How does chronic stress affect SST 
neurons and how does it link to stress-related mood symptoms? The following model of the 
disease process incorporates our observations (Figure 22). A set of genetic predispositions and 
environmental stressors reduces BDNF/GABA-related SST signaling. Several downstream 
mechanisms trigger protein suppression via suppressed EIF2 signaling in selectively vulnerable 
neurons, such as SST-containing interneurons. The following alterations of GABA signaling in 
the local cortical circuits and hyperactive HPA axis activity may impair structure and function of 
cingulate cortex, which gives rise to inefficient information processing underlying behavioral 
phenotypes of mood dysregulation.  
 
 
Figure 23. Proposed disease model illustrating potential cascade of events related to mood dysregulation. 
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6.2 LIMITATIONS AND FUTURE DIRECTIONS 
6.2.1 Confirmation of effects of SST deficits in specific brain regions on emotionality 
The goal of the studies outlined in this dissertation was to determine whether down-regulation of 
SST could be a causative factor in mood dysregulation. We examined anxiety/depressive-like 
behaviors, neuroendocrine phenotype, and the molecular profile of SstKO and SstHZ mice. We 
found that SstKO mice recapitulated behavioral, molecular, and neuroendocrine changes similar to 
those seem in MDD. Hence, the results suggest that SST plays a causal role in mood 
dysregulation. However, it is difficult to conclusively make this statement in global SstKO mice 
without controlling for other confounding factors (region specificity, functional compensation, 
feeding behaviors, etc.) since diseases rarely include full loss of gene function. SST deficits are 
found throughout the brain in human postmortem studies making it difficult to pinpoint regional 
effects. Therefore, future experiments that utilize mouse models with region-specific reduction 
of SST expression are needed to test our hypothesis that SST plays a causal role in mood 
regulation Future experiments could utilize mice with genetic manipulation in which SST is 
selectively knocked down in vivo utilizing viral-mediated RNA interference. An alternative 
approach is to cross mutant animals with “floxed” loci of SST gene to a strain expressing Cre 
recombinase under control of a cell- or tissue-specific promoter. Reducing SST neuronal 
function acutely and chronically in the frontal cortex yields opposite effects on behavioral 
emotionality, suggesting complex network adaptations associated with mood regulation that 
depend on the timeframe and potentially on the set of targeted regions as well (Soumier & 
Sibille, 2014). We predict that loss of SST in the corticolimbic regions would increase 
anxiety/depressive-like behaviors. 
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6.2.2 Confirmation of alterations in protein translation in stressed SST interneurons 
We have argued that the massively suppressed expression of EIF2/EIF4/mTOR signaling in 
stressed SST neurons indicate global protein suppression. The studies within this thesis only 
examined mRNA expression of these signaling pathways. The functional implications of 
reductions in mRNA expression can only be true if there is a concurrent reduction in the cognate 
protein. The concurrent reduction in protein and mRNA needs to be confirmed in future 
experiments, including total protein synthesis and EIF2A protein levels in SST neurons. In 
addition, it is important to confirm alterations in protein translation in subpopulations of SST 
neurons using other stress models. Other stress-sensitive regions, including amygdala and 
hippocampus, are also attractive targets to test whether there are general effects of stress on EIF2 
signaling in SST neurons. Another future research direction is disease progression. If six weeks 
of UCMS significantly reduced SST expression and suppressed Eif2 signaling, whether and how 
these effects persist and accumulate with stress load should be studied in depth; further, how 
long-term changes in protein translation affect inhibitory function of SST neurons in the local 
neural circuitry remains to be determined.  
6.2.3 Identification of unique markers for SST interneurons across species 
How do the mouse findings relate to SST cell pathology in human subjects with major 
depression? Many peptides are difficult to visualize in the cell body under postmortem 
conditions (Doucet & Morrison, 2011). We did not report an experiment utilizing SST protein 
antibody in order to characterize transcriptome profiles of SST interneurons in depressed human 
subjects because of the following potential confound. Some of these interneurons may not 
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express detectable levels of SST protein. This suggests that any labeling study that is performed 
with SST antibody in depressed subjects would be biased since the marker (SST protein) is not 
detectable in some neurons. Therefore, potential alternative markers for SST interneurons that 
are not altered by stress or in major depression are needed to adequately isolate SST neurons. 
6.2.4 Proof of principle experiment: Selective suppression in EIF2 signaling in SST 
interneurons affects long-term modification of neural circuits and mood regulation 
In Chapter 6, we predicted that alterations in EIF2’s translational control in SST neurons leads to 
mood dysregulation. In addition, we found that activation of protein translation via oral treatment 
of an EIF2 kinase inhibitor reversed stress-induced emotionality in mice. Based on these findings, 
we hypothesize that suppressed EIF2 signaling in SST neurons will lead to deregulated cellular 
protein synthesis, which could further contribute to GABAergic inhibition of the dendritic 
portion of pyramidal neurons. This hypothesis can be tested in mice with knock-down of Eif2A 
in SST neurons (specifically in the cingulate cortex), utilizing viral-mediated RNA interference. 
There should be observable dysfunctions at synaptic and circuit levels, such as altered firing 
rates of SST interneurons and pyramidal neurons, as well as reduced presynaptic release 
probability in GABAergic terminals. By altering the baseline levels of protein translation 
through EIF2A, dysregulation of SST neuronal protein synthesis may interfere with synaptic 
modification in response to stress. It will be of interest to determine whether these mice are more 
vulnerable to develop anxiety/depressive-like behaviors after exposure to chronic stress. If our 
hypothesis proves to be correct, approaches to restoring normal levels of protein expression may 
provide a therapeutic strategy for treating mood dysregulation. Using a similar viral-mediated 
approach, emotionality of mice with over-expression of Eif2A in SST neurons can be tested after 
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exposure to chronic stress. We anticipate that these mice would exhibit less stress-induced 
phenotypes to further support our hypothesis that EIF2-regulated translation is involved in mood 
regulation.  
The studies in this thesis only examined the functional role of EIF2 signaling in mood 
regulation using pharmacological manipulations. In Chapter 5, we also identified EIF4 and 
mTOR signaling as top canonical pathways affected in stressed SST neurons. In addition to EIF2 
signaling, the EIF4 and mTOR pathways also play critical roles in protein homeostasis (Gingras 
et al., 1999; Wang & Proud, 2006), and inhibiting protein synthesis during UPR. EIF4 is 
involved in directing ribosomes to the cap structure of mRNAs (Calkhoven et al., 2002). mTOR 
targets EIF4 and S6 protein kinases to mediate cell growth and protein homeostasis in response 
to metabolic and stress signals (Polak & Hall, 2009; Laplante & Sabatini, 2012), and is 
implicated in ketamine antidepressant effects (Li et al., 2010). Therefore, we speculate that EIF4 
and mTOR signaling pathways in SST neurons also have functional implications in mood 
regulation. 
6.3 CONCLUSIONS ON THE CONTRIBUTION OF SST AND EIF2 SIGNALING 
Previous studies from our lab indicate that SST is down-regulated in several regions of MDD 
subjects. Here, our results indicate that SstKO mice have: 1) high baseline/trait emotionality, 2) 
high anxiety/depressive-like syndrome after exposure to chronic stress, 3) robust downregulation 
of GABA- and BDNF- related transcript, and 4) high basal levels of plasma corticosterone. 
Using a mouse stress model of depression (UCMS), we found that SST-containing interneurons 
were selectively vulnerable to chronic stress. EIF2-related transcripts were robust down-
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regulated in stressed SST neurons. Re-activation of EIF2 pathway by an EIF2A kinase inhibitor 
can reduce stress-induced anxiety/depressive-like behaviors in mice. In conclusion, dysfunction 
of SST and SST neurons could translate to suboptimal inhibitory control of cortical local circuits, 
priming the system for deregulated physiological responses to stress and inducing multiple 
endophenotypes associated with mood dysregulation. 
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APPENDIX A 
A HUMAN-MOUSE CONSERVED SEX BIAS IN AMYGDALA GENE EXPRESSION 
RELATED TO CIRCADIAN CLOCK AND ENERGY METABOLISM 
Molecular Brain. 2011 4:18. 
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Abstract 
 
Background: Major depression affects twice as many women as men, but the underlying 
molecular mechanisms responsible for the heightened female vulnerability are not known. The 
amygdala, composed of heterogeneous subnuclei, participates in multiple functional circuits 
regulating emotional responses to stress. We hypothesized that sex differences in molecular 
structure may contribute to differential mood regulation and disease vulnerability.  
 
Findings: Using gene arrays followed by quantitative PCR validation, we compared the 
transcriptome profiles between sexes in human and mouse amygdala. We now report sexually 
dimorphic features of transcriptomes in the basolateral nucleus of the amygdala, and these 
features are highly conserved across species. A functional analysis of differential gene 
expression showed that mitochondrial-related gene groups were identified as the top biological 
pathways associated with sexual dimorphism in both species.  
 
Conclusions: These results suggest that the basolateral amygdala is a sexually dimorphic 
structure, featuring a regulatory cascade of mitochondrial function and circadian rhythm, 
potentially linked through sirtuins and hormone nuclear receptors. Hence, baseline differences in 
amygdalar circadian regulation of cellular metabolism may contribute to sex-related differences 
in mood regulation and vulnerability to major depression. 
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Introduction 
 
Males and females differ in behavior and brain structure, as well as in prevalence of 
neuropsychiatric disorders. The greater prevalence of major depression and rapid cycling bipolar 
disorder in women (Kendler, 1998; Tondo & Baldessarini, 1998) highlights the importance of 
studying potential mechanisms for sex differences. Sex chromosome- and hormone-linked genes 
may directly affect sexually dimorphic neurobiology (Jazin & Cahill). For example, sex 
hormones regulate the size of the medial amygdala and bed nucleus of the stria terminalis during 
development (Hines et al., 1992). The lateral (LA) and basal (basolateral; throughout the article 
we refer to human BA and mouse BLA) nuclei of the amygdala have been identified as critical 
sites for learned fear and emotion regulation in healthy subjects and in patients with mood 
disorders (Sheline et al., 2001; Sibille et al., 2009a), but little is known about their sexual 
dimorphism. The isolation of subnuclei from the amygdala complex improves microarray 
sensitivity to detect differences in gene expression by reducing sample heterogeneity, and could 
facilitate the subsequent identification of genetic sex differences. To characterize sex differences 
in the intrinsic molecular properties of the amygdala, we examined the presence of sexually 
dimorphic patterns of gene expression in the basolateral nuclei of the amygdala using 
postmortem samples from control human subjects and mice. 
 
Methods 
Human Brain Samples 
Postmortem amygdala samples from 12 healthy male controls and 12 healthy female controls 
(age = 39-64 years) were obtained from the University of Pittsburgh Brain Donation Program 
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(Table 1), as previously described (Sibille et al., 2009a). Male and female groups were matched 
in pairs as closely as possible on the basis of RNA integrity, pH, post-mortem interval, age, and 
sex, and the groups did not differ on any of these parameters (p>0.05; Table 1). All subjects died 
suddenly without prolonged agonal periods. See (Sibille et al., 2009a) for additional details. In 
contrast to the light acetylcholinesterase (AChE)-stained LA across species, human BA and 
mouse BLA contained the heavy stained AChE-positive neuropil in the amygdala (Svendsen & 
Bird, 1985; Kitt et al., 1994), implying that human BA and LA anatomically correspond to the 
mouse BLA and LA according to the well-defined AChE boundaries. Hence, based on the 
distribution of AChE activity and thionin staining, human lateral (LA) and basal (BA) amygdala 
nuclei were defined and separately harvested from 20-μm cryostat sections using a clean RNase-
free pipette tip. All procedures were approved by the University of Pittsburgh's Committee for 
the Oversight of Research Involving the Dead and Institutional Review Board for Biomedical 
Research. 
 
Mouse Brain Samples 
Brains from adult C57BL/6J mice (n = 5 per sex; pooled by 2 from 10 mice/group, 3 months of 
age) were harvested, fresh frozen and cryo-sectioned at 20 μm on UV-treated laser-capture 
microscopy slides (Leica Microsystems, Wetzlar, Germany). Sections on the slides were dried 
and stored at −80°C until used. Lateral (LA) to basolateral (BLA) amygdala nuclei were 
visualized with rapid thionin staining and dissected with the Leica LMD 6500 laser 
microdissection system. All mice were maintained on a 12-hour light-dark cycle (lights on 06:00 
and lights off on 18:00) with ad libitum food and water. All procedures were approved by the 
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University of Pittsburgh Institutional Animal Care and Use Committee (protocol # 0911014A-2, 
Animal Assurance # A3187-01).  
 
RNA extraction for Microarray Samples 
Total RNA was extracted using the RNeasy Plus Micro Kit (QIAGEN, Valencia, CA) and 
processed for microarray analysis according to manufacturer’s protocol. RNA samples were 
amplified with Illumina TotalPrep RNA Amplification Kit (for human tissue; Illumina, San 
Diego, CA) and Nugen WT-Ovation Pico RNA Amplification System (for mouse tissue; NuGen, 
San Carlos, CA). The fragmented labeled cRNA samples were processed and hybridized to 
microarrays (Human HT-12v3 and MouseWG-6v2.0 BeadChips).  
 
Array Data Analysis 
For statistical analysis, the log2-transformed signal intensities of probe-sets that passed the initial 
expression filters (<30% missing values, detection p-value >0.1), were extracted and 
renormalized to the same mean and variance across arrays in order to control for any effects of 
batch. Discovery threshold for male/female differences were applied in both species (two-tailed 
t-test p-value <0.05; >20% effect size). Functional analyses were performed on the identified 
gene list using the Ingenuity Pathways Knowledge Base [9] and compared across species. 
 
Real-time Quantitative PCR (qPCR) Data Analysis 
Separate RNA samples were reverse-transcribed using QScript cDNA super mix 
(QuantaBioscience, Gaithersburg, MD) using a combination of oligo (dT) and random primers. 
Each PCR reaction was performed in triplicate and compared to three internal controls (GAPDH, 
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beta-actin and cyclophilin). All designed primer sequences were designed with Primer3Plus 
(Additional File 1, table S1). Results were calculated as the geometric mean of relative 
intensities compared to the three internal controls. Validation of the array results was considered  
at p<0.05, using one-tailed unpaired t-test. 
 
Results 
Using exploratory criteria we generated large and informative parallel human/mouse 
transcriptome datasets from male and female BA (BLA in mice) and LA nuclei of the amygdala. 
As an internal control to assess the sensitivity of the array approach, all detected Y-chromosome 
genes (male-specific) displayed significantly male-biased expression, and expression of 
numerous X-linked genes showed a female bias (Figure 1). In humans, 1335 sex-biased 
autosomal genes were identified in BA (Additional File 2, table S2), and fewer (n =165) in LA 
(Additional File 3, table S3). In mice, ~1% of autosomal genes displayed sex-biased expression 
(BLA, n =515, Additional File 4, table S4; LA, n =556, Additional File 5, table S5).  
     To reduce false discovery and focus on the most relevant changes, we characterized the 
functional and cross-species relatedness of autosomal sex-biased gene sets using the Ingenuity 
Pathways Analysis (IPA) database. Mitochondrial-related functions were consistently identified 
among the top four most-represented pathways in human BA (p<1.57E-06), mouse BA (p<8.37E-
03) and mouse LA (p<6.72E-02). Assembly of RNA Polymerase III Complex was the only 
identified canonical pathway in human LA and was at trend level (p <0.1).  
         Within the mitochondrial-related functions, genes encoding enzymes of the mitochondrial 
electron transport chain (ETC) consistently displayed high male-biased expression (Figure 2A). 
Also, two genes coding for mitochondria-localized sirtuins (SIRT3, SIRT5), which serve as 
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metabolic regulators of circadian rhythms by utilizing NAD+ (Asher et al., 2008), also showed 
similar high male-biased expression in human BA and mouse BLA. Of related interest was the 
identification of sex-biased circadian rhythm signaling in human BA (IPA, p<5.39E-04) and 
mouse LA (p<3.54E-02), which included conserved high female-biased expression of selected 
circadian clock genes (e.g., Period 2 and trend-level for CLOCK; Figure 2A). Intriguingly, as 
nuclear receptors link the circadian clock to metabolism (Yang et al., 2006), retinoic acid orphan 
receptor β (RORB) and thyroid hormone receptor α (THRA) displayed high female-biased 
expression in human BA (RORB: average log ratio [alr] = 0.29, p <0.026; THRA: alr =0.31, p 
<0.013). 
   The accuracy and reproducibility of the approach was assessed by qPCR on 
independent samples. 12 genes out of 18 tested were individually confirmed (p<0.05; same 
direction; Figure 2B). Overall, the qPCR validation results were highly correlated with array data 
using Pearson tests for significance (r = 0.86, p < 2.5E-06; Figure 2D).  
We next evaluated the anatomical extent of the observed sex-biased gene profiles in other 
brain areas using existing human array data in cortical regions (Galfalvy et al., 2003). Numerous 
ETC and SIRT genes in dorsolateral prefrontal cortex (Brodman area 9 [BA9]; Figure 2C), and 
fewer in the ventrolateral prefrontal cortex (Brodman area 47 [BA47]; Figure 2C) and anterior 
cingulate cortex (ACC; Figure 2C), consistently displayed high male-biased expression, 
suggesting variable levels of regional conservation and amygdala enrichment.  
      Notably, within the limited cohort size and age range, we did not observe statistically 
significant age-related effects for genes confirmed by qPCR, except for male-biased ATP 
synthase genes (ATP5A1, r = -0.78, p < 0.005; ATP6VOD1, r = -0.58, p < 0.05) in human male 
amygdala. Since no information was available for menopause or estrogen replacement treatment 
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for the human female subjects, we interpreted these results as indicative of sexual dimorphism 
independently of age or estrogen status, although this will need to be tested in larger cohorts.  
 
Discussion 
 
We report sexually dimorphic gene expression profiles in the BA nucleus of the amygdala in 
human subjects. Changes at the level of single genes extend to homologous BLA nucleus in the 
mouse amygdala, albeit to a lesser extent. At the functional level, mitochondrial-related gene 
groups were consistently identified as the top biological pathways associated with male/female 
differences in both species. Together with prominent differences in other gene groups (Figure 2), 
our results suggest a sexual dimorphism in the expression level of an evolutionarily conserved 
pathway - circadian clock and mitochondrial function, potentially linked through sirtuin and 
nuclear hormone receptors. 
      In experimental models, circadian genes modulate energy metabolism by setting the 
periodic oscillations of expression and activity of enzymes to influence physiological and 
behavioral functions. Substantial evidence has shown that patients with major depression or 
bipolar disorder often display abnormalities in circadian rhythm, such as disturbances in the 
sleep/wake cycle and diurnal mood changes. Genetics studies have found associations with 
CLOCK, PER1-3, and CRY1 , and Sirtuin genes in mood disorders (Soria et al.; Roybal et al., 
2007; Hampp et al., 2008; Abe et al., 2011). In molecular/genetic studies, mitochondrial 
dysfunction has been associated with mood disorders (Konradi et al., 2004; Rollins et al., 2009), 
and mood disorders are common in patients with mitochondrial disorders (Fattal et al., 2007). 
Thus, our findings suggest that baseline sexual dimorphism in mitochondrial density or functions 
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may influence energy availability in the amygdala. Notably, while mitochondrial function was 
systemically identified as a top sex-biased gene family across species, the species-specific 
orthologous genes were not necessarily and systematically the same, but very close functionally 
(Figure 2E). Because of identification of mitochondrial-related genes with closely related 
functions and locations across species, we speculate that the sex-biased mitochondria profile may 
be under conserved transcription control to display similar sexual dimorphism across species.  
 Limitations of this study are noted. The results will need to be confirmed at the protein and 
functional levels in independent and larger cohorts. Similarly, the potential contribution of race-
specific amygdala gene expression will need to be assessed in larger cohorts. It is also unclear 
whether our findings in mid-life adults can be generalized to adolescent and elderly populations. 
Here we identified age effects in 2 of the 18 genes validated by qPCR, suggesting that aging may 
not contribute to the evolutionary conserved genetic sex differences in amygdala. In addition, 
this study sampled 10 intact female mice and 12 female human subjects from 39-64 years old, 
which should considerably lower the impact of variable estrogen levels on our findings of 
genetic sex difference, although we cannot exclude residual effects. 
      In conclusion, we present evidence for significant male/female differences in amygdala 
gene expression across species. Delineating the contribution of mitochondrial and circadian 
signaling in mood disorders will require additional work. For instance, sex-biased gene 
expression of circadian clock, nuclear hormone receptors, mitochondrial sirtuins and electron 
chain enzymes in an interlocking-feedback loop, may functionally translate into differential 
amygdala responsiveness (Figure 2E). This loop may lead to sex differences in metabolic 
capacity to meet energy demand, and might potentially contribute to the greater female 
vulnerability to mood disorders.  
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APPENDIX B 
STATISTICAL RESULTS OF BEHAVIORS IN SST HETEROZYGOUS MOUSE 
Table 1. Time in Open Arms of Elevated Plus Maze 
  
      Two-way ANOVA Ordinary 
    Alpha 0.05 
    
      Source of 
Variation 
% of total 
variation 
P 
value 
P value 
summary Significant? 
 Interaction 0.2713 0.6656 ns No 
 genotype 0.3743 0.6118 ns No 
 treatment 2.963 0.1561 ns No 
 
      ANOVA table SS DF MS F (DFn, DFd) P value 
Interaction 151.1 1 151.1 
F (1, 67) = 
0.1884 
P = 
0.6656 
genotype 208.5 1 208.5 
F (1, 67) = 
0.2600 
P = 
0.6118 
treatment 1650 1 1650 F (1, 67) = 2.058 
P = 
0.1561 
Residual 53737 67 802 
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Table 2. % Crosses into Open Arms of Elevated Plus Maze 
      Two-way 
ANOVA Ordinary 
    Alpha 0.05 
    
      Source of 
Variation 
% of total 
variation 
P 
value 
P value 
summary Significant? 
 Interaction 0.6526 0.5087 ns No 
 genotype 0.2146 0.7044 ns No 
 treatment 0.03108 0.8851 ns No 
 
      ANOVA table SS DF MS F (DFn, DFd) P value 
Interaction 28.53 1 28.53 
F (1, 67) = 
0.4414 
P = 
0.5087 
genotype 9.384 1 9.384 
F (1, 67) = 
0.1452 
P = 
0.7044 
treatment 1.359 1 1.359 
F (1, 67) = 
0.02103 
P = 
0.8851 
Residual 4331 67 64.64 
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Table 3. Total Crosses in Elevated Plus Maze 
    
         Two-way ANOVA Ordinary 
       Alpha 0.05 
       
         
Source of Variation 
% of total 
variation P value 
P value 
summary Significant? 
    Interaction 0.4 0.5773 ns No 
    genotype 1.671 0.2565 ns No 
    treatment 10.87 0.0048 ** Yes 
    
         
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P 
value 
   
Interaction 19.91 1 19.91 
F (1, 67) = 
0.3136 
P = 
0.5773 
   
genotype 83.15 1 83.15 
F (1, 67) = 
1.310 
P = 
0.2565 
   
treatment 541 1 541 
F (1, 67) = 
8.522 
P = 
0.0048 
   Residual 4253 67 63.48 
     
         Tukey's multiple 
comparisons test Mean Diff. 
95% CI 
of diff. Significant? Summary 
    WT:Control vs. 
WT:UCMS -6.714 
-13.19 to 
-0.2361 Yes * 
    WT:Control vs. 
HZ:Control -3.289 
-10.70 to 
4.119 No ns 
    WT:Control vs. 
HZ:UCMS -7.842 
-14.81 to 
-0.8764 Yes * 
    WT:UCMS vs. 
HZ:Control 3.425 
-3.983 to 
10.83 No ns 
    WT:UCMS vs. 
HZ:UCMS -1.128 
-8.094 to 
5.838 No ns 
    HZ:Control vs. 
HZ:UCMS -4.553 
-12.39 to 
3.285 No ns 
    
         Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF 
WT:Control vs. 
WT:UCMS 28.1 34.81 -6.714 2.459 21 21 3.862 67 
WT:Control vs. 
HZ:Control 28.1 31.38 -3.289 2.812 21 13 1.654 67 
WT:Control vs. 
HZ:UCMS 28.1 35.94 -7.842 2.644 21 16 4.195 67 
WT:UCMS vs. 
HZ:Control 34.81 31.38 3.425 2.812 21 13 1.723 67 
WT:UCMS vs. 
HZ:UCMS 34.81 35.94 -1.128 2.644 21 16 0.6034 67 
HZ:Control vs. 
HZ:UCMS 31.38 35.94 -4.553 2.975 13 16 2.164 67 
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Table 4. Time in Center of Open Field 
   
      Two-way ANOVA Ordinary 
    Alpha 0.05 
    
      
Source of Variation 
% of total 
variation P value 
P value 
summary Significant? 
 Interaction 4.283 0.0716 ns No 
 genotype 0.2195 0.6799 ns No 
 treatment 7.265 0.02 * Yes 
 
      ANOVA table SS DF MS F (DFn, DFd) P value 
Interaction 12134 1 12134 
F (1, 67) = 
3.350 
P = 
0.0716 
genotype 621.8 1 621.8 
F (1, 67) = 
0.1717 
P = 
0.6799 
treatment 20581 1 20581 
F (1, 67) = 
5.683 
P = 
0.0200 
Residual 242657 67 3622 
        
      Tukey's multiple 
comparisons test Mean Diff. 
95% CI of 
diff. Significant? Summary 
 
WT:Control vs. WT:UCMS 61.43 
12.50 to 
110.4 Yes ** 
 
WT:Control vs. HZ:Control 20.64 
-35.32 to 
76.60 No ns 
 
WT:Control vs. HZ:UCMS 28.71 
-23.91 to 
81.32 No ns 
 
WT:UCMS vs. HZ:Control -40.79 
-96.74 to 
15.17 No ns 
 
WT:UCMS vs. HZ:UCMS -32.72 
-85.34 to 
19.90 No ns 
 
HZ:Control vs. HZ:UCMS 8.067 
-51.14 to 
67.27 No ns 
  
 
 
 
 
 
 
 116 
Table 5. % Distance in the Center of Open Field 
   
        Two-way ANOVA Ordinary 
      Alpha 0.05 
      
        
Source of Variation 
% of total 
variation P value 
P value 
summary Significant? 
   Interaction 1.603 0.2701 ns No 
   genotype 0.1558 0.7299 ns No 
   treatment 9.515 0.0086 ** Yes 
   
        
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P 
value 
  
Interaction 84.38 1 84.38 
F (1, 67) = 
1.237 
P = 
0.2701 
  
genotype 8.201 1 8.201 
F (1, 67) = 
0.1202 
P = 
0.7299 
  
treatment 500.8 1 500.8 
F (1, 67) = 
7.340 
P = 
0.0086 
  Residual 4572 67 68.23 
    
        Tukey's multiple 
comparisons test Mean Diff. 
95% CI 
of diff. Significant? Summary 
   WT:Control vs. 
WT:UCMS 7.645 
0.9289 to 
14.36 Yes * 
   WT:Control vs. 
HZ:Control 1.531 
-6.149 to 
9.212 No ns 
   WT:Control vs. 
HZ:UCMS 4.727 
-2.495 to 
11.95 No ns 
   WT:UCMS vs. 
HZ:Control -6.114 
-13.79 to 
1.566 No ns 
   WT:UCMS vs. 
HZ:UCMS -2.919 
-10.14 to 
4.303 No ns 
   HZ:Control vs. 
HZ:UCMS 3.195 
-4.931 to 
11.32 No ns 
   
        Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q 
WT:Control vs. 
WT:UCMS 30.43 22.78 7.645 2.549 21 21 4.241 
WT:Control vs. 
HZ:Control 30.43 28.9 1.531 2.915 21 13 0.7429 
WT:Control vs. 
HZ:UCMS 30.43 25.7 4.727 2.741 21 16 2.439 
WT:UCMS vs. 
HZ:Control 22.78 28.9 -6.114 2.915 21 13 2.966 
WT:UCMS vs. 
HZ:UCMS 22.78 25.7 -2.919 2.741 21 16 1.506 
HZ:Control vs. 
HZ:UCMS 28.9 25.7 3.195 3.084 13 16 1.465 
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Table 6. Total Distance in Open Field 
     
         Two-way ANOVA Ordinary 
       Alpha 0.05 
       
         
Source of Variation 
% of total 
variation P value 
P value 
summary Significant? 
    Interaction 1.627 0.2247 ns No 
    genotype 0.04059 0.8471 ns No 
    treatment 27.29 < 0.0001 **** Yes 
    
         
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P 
value 
   
Interaction 44062 1 44062 
F (1, 67) = 
1.502 
P = 
0.2247 
   
genotype 1099 1 1099 
F (1, 67) = 
0.03746 
P = 
0.8471 
   
treatment 739189 1 739189 
F (1, 67) = 
25.19 
P < 
0.0001 
   Residual 1966000 67 29345 
     
         Tukey's multiple 
comparisons test Mean Diff. 
95% CI 
of diff. Significant? Summary 
    WT:Control vs. 
WT:UCMS -157.4 
-296.7 to 
-18.12 Yes * 
    WT:Control vs. 
HZ:Control 58.87 
-100.4 to 
218.2 No ns 
    WT:Control vs. 
HZ:UCMS -200.2 
-350.0 to 
-50.44 Yes ** 
    WT:UCMS vs. 
HZ:Control 216.3 
56.99 to 
375.6 Yes ** 
    WT:UCMS vs. 
HZ:UCMS -42.81 
-192.6 to 
107.0 No ns 
    HZ:Control vs. 
HZ:UCMS -259.1 
-427.6 to 
-90.56 Yes *** 
    
         Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q DF 
WT:Control vs. 
WT:UCMS 709.1 866.5 -157.4 52.87 21 21 4.211 67 
WT:Control vs. 
HZ:Control 709.1 650.2 58.87 60.45 21 13 1.377 67 
WT:Control vs. 
HZ:UCMS 709.1 909.3 -200.2 56.85 21 16 4.981 67 
WT:UCMS vs. 
HZ:Control 866.5 650.2 216.3 60.45 21 13 5.059 67 
WT:UCMS vs. 
HZ:UCMS 866.5 909.3 -42.81 56.85 21 16 1.065 67 
HZ:Control vs. 
HZ:UCMS 650.2 909.3 -259.1 63.96 13 16 5.728 67 
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Table 7. Latency to feed in Novelty Suppressed Feeding Test 
  
      Two-way ANOVA Ordinary 
    Alpha 0.05 
    
      
Source of Variation 
% of total 
variation P value 
P value 
summary Significant? 
 Interaction 0.1657 0.7164 ns No 
 genotype 0.4196 0.5635 ns No 
 treatment 15.68 0.0007 *** Yes 
 
      ANOVA table SS DF MS F (DFn, DFd) P value 
Interaction 2631 1 2631 
F (1, 67) = 
0.1330 
P = 
0.7164 
genotype 6663 1 6663 
F (1, 67) = 
0.3370 
P = 
0.5635 
treatment 248955 1 248955 
F (1, 67) = 
12.59 
P = 
0.0007 
Residual 1325000 67 19773 
  
      Tukey's multiple 
comparisons test Mean Diff. 
95% CI of 
diff. Significant? Summary 
 
WT:Control vs. WT:UCMS -108.4 
-222.8 to 
5.904 No ns 
 
WT:Control vs. HZ:Control -7.348 
-138.1 to 
123.4 No ns 
 
WT:Control vs. HZ:UCMS -140.6 
-263.6 to -
17.68 Yes * 
 
WT:UCMS vs. HZ:Control 101.1 
-29.66 to 
231.8 No ns 
 
WT:UCMS vs. HZ:UCMS -32.19 
-155.1 to 
90.75 No ns 
 
HZ:Control vs. HZ:UCMS -133.3 
-271.6 to 
5.060 No ns 
  
Test details 
Mean 
1 
Mean 
2 
Mean 
Diff. 
SE of 
diff. N1 N2 q 
WT:Control vs. 
WT:UCMS 74.19 182.6 -108.4 43.39 21 21 3.534 
WT:Control vs. 
HZ:Control 74.19 81.54 -7.348 49.62 21 13 0.2094 
WT:Control vs. 
HZ:UCMS 74.19 214.8 -140.6 46.66 21 16 4.262 
WT:UCMS vs. 
HZ:Control 182.6 81.54 101.1 49.62 21 13 2.881 
WT:UCMS vs. 
HZ:UCMS 182.6 214.8 -32.19 46.66 21 16 0.9757 
HZ:Control vs. 
HZ:UCMS 81.54 214.8 -133.3 52.5 13 16 3.59 
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Table 9. Sucrose consumption in Sucrose Preference Test 
  
        Two-way ANOVA Ordinary 
      Alpha 0.05 
      
        
Source of Variation 
% of total 
variation P value 
P value 
summary Significant? 
   Interaction 0.819 0.4248 ns No 
   genotype 0.8003 0.4301 ns No 
   treatment 15.8 0.0008 *** Yes 
   
        
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P 
value 
  
Interaction 0.002 1 0.002 
F (1, 66) = 
0.6451 
P = 
0.4248 
  
genotype 0.001954 1 0.001954 
F (1, 66) = 
0.6304 
P = 
0.4301 
  
treatment 0.03858 1 0.03858 
F (1, 66) = 
12.44 
P = 
0.0008 
  Residual 0.2046 66 0.0031     
  
        Tukey's multiple 
comparisons test Mean Diff. 
95% CI of 
diff. Significant? Summary 
   WT:Control vs. 
WT:UCMS 0.03693 
-0.008925 to 
0.08278 No ns 
   WT:Control vs. 
HZ:Control -0.02165 
-0.07344 to 
0.03014 No ns 
   WT:Control vs. 
HZ:UCMS 0.03705 
-0.01165 to 
0.08575 No ns 
   WT:UCMS vs. 
HZ:Control -0.05858 
-0.1109 to -
0.006292 Yes * 
   WT:UCMS vs. 
HZ:UCMS 0.000125 
-0.04910 to 
0.04935 No ns 
   HZ:Control vs. 
HZ:UCMS 0.0587 
0.003903 to 
0.1135 Yes * 
   
        Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q 
WT:Control vs. 
WT:UCMS 0.1614 0.1245 0.03693 0.0174 21 20 3.002 
WT:Control vs. 
HZ:Control 0.1614 0.1831 -0.02165 0.01965 21 13 1.558 
WT:Control vs. 
HZ:UCMS 0.1614 0.1244 0.03705 0.01848 21 16 2.836 
WT:UCMS vs. 
HZ:Control 0.1245 0.1831 -0.05858 0.01984 20 13 4.176 
WT:UCMS vs. 
HZ:UCMS 0.1245 0.1244 0.000125 0.01868 20 16 0.009465 
HZ:Control vs. 
HZ:UCMS 0.1831 0.1244 0.0587 0.02079 13 16 3.993 
 
 120 
Table 10. Sucrose preference in Sucrose Preference Test 
  
        Two-way ANOVA Ordinary 
      Alpha 0.05 
      
        
Source of Variation 
% of total 
variation P value 
P value 
summary Significant? 
   Interaction 1.762 0.2576 ns No 
   genotype 2.05 0.2224 ns No 
   treatment 5.853 0.0413 * Yes 
   
        
ANOVA table SS DF MS 
F (DFn, 
DFd) P value 
  
Interaction 345.6 1 345.6 
F (1, 66) = 
1.304 
P = 
0.2576 
  
genotype 402.1 1 402.1 
F (1, 66) = 
1.517 
P = 
0.2224 
  
treatment 1148 1 1148 
F (1, 66) = 
4.331 
P = 
0.0413 
  Residual 17493 66 265 
    
        Tukey's multiple 
comparisons test Mean Diff. 
95% CI of 
diff. Significant? Summary 
   WT:Control vs. 
WT:UCMS 12.77 
-0.6330 to 
26.18 No ns 
   WT:Control vs. 
HZ:Control -0.3556 
-15.50 to 
14.79 No ns 
   WT:Control vs. 
HZ:UCMS 3.367 
-10.87 to 
17.61 No ns 
   WT:UCMS vs. 
HZ:Control -13.13 
-28.42 to 
2.158 No ns 
   WT:UCMS vs. 
HZ:UCMS -9.407 
-23.80 to 
4.985 No ns 
   HZ:Control vs. 
HZ:UCMS 3.722 
-12.30 to 
19.74 No ns 
   
        Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q 
WT:Control vs. 
WT:UCMS 90.06 77.29 12.77 5.087 21 20 3.551 
WT:Control vs. 
HZ:Control 90.06 90.42 -0.3556 5.745 21 13 0.08753 
WT:Control vs. 
HZ:UCMS 90.06 86.7 3.367 5.402 21 16 0.8813 
WT:UCMS vs. 
HZ:Control 77.29 90.42 -13.13 5.8 20 13 3.201 
WT:UCMS vs. 
HZ:UCMS 77.29 86.7 -9.407 5.461 20 16 2.436 
HZ:Control vs. 
HZ:UCMS 90.42 86.7 3.722 6.079 13 16 0.8659 
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Table 11. Emotionality Z-score 
        Two-way ANOVA Ordinary 
      Alpha 0.05 
      
        
Source of Variation 
% of total 
variation P value 
P value 
summary Significant? 
   Interaction 0.3644 0.5819 ns No 
   genotype 0.3836 0.5722 ns No 
   treatment 19.35 0.0001 *** Yes 
   
        
ANOVA table SS DF MS F (DFn, DFd) 
P 
value 
  
Interaction 0.1459 1 0.1459 
F (1, 66) = 
0.3062 
P = 
0.5819 
  
genotype 0.1536 1 0.1536 
F (1, 66) = 
0.3223 
P = 
0.5722 
  
treatment 7.744 1 7.744 
F (1, 66) = 
16.25 
P = 
0.0001 
  Residual 31.45 66 0.4765 
    
        Tukey's multiple 
comparisons test Mean Diff. 
95% CI of 
diff. Significant? Summary 
   WT:Control vs. 
WT:UCMS -0.7704 
-1.339 to -
0.2020 Yes ** 
   WT:Control vs. 
HZ:Control 0.002418 
-0.6397 to 
0.6445 No ns 
   WT:Control vs. 
HZ:UCMS -0.5821 
-1.186 to 
0.02170 No ns 
   WT:UCMS vs. 
HZ:Control 0.7728 
0.1247 to 
1.421 Yes * 
   
WT:UCMS vs. HZ:UCMS 0.1884 
-0.4219 to 
0.7986 No ns 
   
HZ:Control vs. HZ:UCMS -0.5845 
-1.264 to 
0.09488 No ns 
   
        Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q 
WT:Control vs. 
WT:UCMS -0.001429 0.769 -0.77 0.2157 21 20 5.1 
WT:Control vs. 
HZ:Control -0.001429 -0.0038 0.0024 0.2436 21 13 0 
WT:Control vs. 
HZ:UCMS -0.001429 0.5806 -0.582 0.2291 21 16 3.6 
WT:UCMS vs. 
HZ:Control 0.769 -0.0038 0.7728 0.2459 20 13 4.4 
WT:UCMS vs. HZ:UCMS 0.769 0.5806 0.1884 0.2315 20 16 1.2 
HZ:Control vs. HZ:UCMS -0.003846 0.5806 -0.585 0.2577 13 16 3.2 
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Table 12. Locomotion Z-score 
        Two-way ANOVA Ordinary 
      Alpha 0.05 
      
        
Source of Variation 
% of total 
variation P value 
P value 
summary Significant? 
   Interaction 0.01046 0.924 ns No 
   genotype 0.7009 0.4361 ns No 
   treatment 21.69 < 0.0001 **** Yes 
   
        
ANOVA table SS DF MS 
F (DFn, 
DFd) 
P 
value 
  
Interaction 0.009187 1 0.009187 
F (1, 67) = 
0.009161 
P = 
0.9240 
  
genotype 0.6155 1 0.6155 
F (1, 67) = 
0.6138 
P = 
0.4361 
  
treatment 19.05 1 19.05 
F (1, 67) = 
18.99 
P < 
0.0001 
  Residual 67.19 67 1.003 
    
        Tukey's multiple 
comparisons test Mean Diff. 
95% CI of 
diff. Significant? Summary 
   WT:Control vs. 
WT:UCMS -1.034 
-1.848 to -
0.2196 Yes ** 
   WT:Control vs. 
HZ:Control -0.1668 
-1.098 to 
0.7643 No ns 
   WT:Control vs. 
HZ:UCMS -1.247 
-2.123 to -
0.3715 Yes ** 
   WT:UCMS vs. 
HZ:Control 0.867 
-0.06410 to 
1.798 No ns 
   WT:UCMS vs. 
HZ:UCMS -0.2132 
-1.089 to 
0.6623 No ns 
   HZ:Control vs. 
HZ:UCMS -1.08 
-2.065 to -
0.09509 Yes * 
   
        Test details Mean 1 Mean 2 Mean Diff. SE of diff. N1 N2 q 
WT:Control vs. 
WT:UCMS -0.00143 1.032 -1.034 0.309 21 21 4.731 
WT:Control vs. 
HZ:Control -0.00143 0.1654 -0.1668 0.3534 21 13 0.6675 
WT:Control vs. 
HZ:UCMS -0.00143 1.246 -1.247 0.3323 21 16 5.307 
WT:UCMS vs. 
HZ:Control 1.032 0.1654 0.867 0.3534 21 13 3.47 
WT:UCMS vs. 
HZ:UCMS 1.032 1.246 -0.2132 0.3323 21 16 0.9075 
HZ:Control vs. 
HZ:UCMS 0.1654 1.246 -1.08 0.3739 13 16 4.086 
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